research companies medicine

Claim $100 of Free Data

Top 15 Clinical Research Companies: Leaders in Medical Innovation

In the healthcare industry, the number of contract research organizations in the US has reached 2,823 in 2023. This marks a subtle but significant increase of 0.9% compared to the previous year.

This increase signals a vital trend: the growing complexity of finding the best clinical research companies in a crowded field. These organizations aren’t just businesses; they’re important in advancing medicine and developing drugs and therapies.

With such an important task, choosing the right company becomes essential. In this guide, we’ve looked closely at many companies along with their strengths and weaknesses and made a list of the top clinical research organizations.

By the end, you’ll know which company is the best fit for your needs.

Table of Contents

Quick List of Top 15 Clinical Research Companies

Here is a quick overview of the best companies of clinical research:

IQVIA: Best for data-driven insights and advanced analytics in healthcare research.
ICON: Best for comprehensive clinical development services and therapeutic expertise.
Parexel: Best for global biopharmaceutical services, emphasizing regulatory and clinical trial excellence.
Syneos Health: Best for integrated biopharmaceutical solutions and clinical-commercial capabilities.
PPD: Best for drug development services with innovative, technology-enhanced trial strategies.
Labcorp: Best for comprehensive clinical testing and diagnostics services with global reach.
Medpace: Best for expertise in clinical research and regulatory affairs for pharmaceutical companies.
Charles River Laboratories: Best for preclinical research and development services, including animal testing and research models.
PRA Health Sciences: Best for clinical trial expertise and integrated solutions for biopharmaceutical development.
AdvanCell: Best for innovative cell and tissue-based research solutions for life science industries.
Dynata: Best for data-driven insights and market research services for informed decision-making.
Covance: Best for end-to-end drug development solutions, from preclinical to post-marketing.
MedNet: Best for technology solutions and eClinical platforms for streamlined clinical trials.
Fisher Clinical Services Inc: Best for global logistics and supply chain services for clinical trial materials.
Worldwide Clinical Trials: Best for specialized CRO offering personalized clinical research solutions.

3 Best Clinical Research Organizations: Comparison Chart

Here’s a comparison table to highlight the key features and differences among the best companies of clinical research. This table aims to provide a quick overview of each company’s unique strengths and areas of expertise in the pharmaceutical and healthcare research sector.

3 Top Clinical Research Organization List For Advanced Medical Discoveries

Now, we’ll explore the top clinical research organizations (CROs) dedicated to advancing medical discoveries. Let’s jump into the details of these exceptional organizations.

IQVIA is a global leader in clinical research and healthcare data analytics. They play a crucial role in the medical field by providing comprehensive data, advanced analytics, and expert insights. This helps pharmaceutical and healthcare companies make smarter, more effective decisions.

Why is IQVIA among the best? Their strength lies in their vast database and advanced technology, which enable them to analyze complex healthcare data efficiently. This leads to a better understanding of diseases, more effective treatments, and faster drug development.

IQVIA’s work is essential because it speeds up the process of bringing new medicines to the market, ultimately benefiting patients worldwide. In short, IQVIA is a key catalyst in advancing global healthcare.

About IQVIA

Founding Team: Dennis Gillings
Founding Year: 1982
Company Size: 86,000

Features of IQVIA

IQVIA, a prominent player in the life sciences sector, is dedicated to advancing healthcare through connected intelligence. Here are some key features of IQVIA in the world of clinical research:

Innovative Clinical Development

IQVIA is reimagining clinical development by intelligently connecting data, technology, and analytics. This approach leads to faster decision-making and reduced risk, enabling the delivery of life-changing therapies more quickly.

Efficient Payment Systems for Clinical Trials

They have simplified the process of paying sites involved in clinical trials. IQVIA offers the capability to make payments within 30 days, even in challenging locations. This significantly reduces the administrative burden of managing clinical trial payments by up to 90%.

Decentralized Trials Expertise

The company has conducted over 500 studies in more than 75 countries, covering over 30 indications using decentralized trial methodologies. This demonstrates their capability in managing complex, multinational clinical trials.

Global Reach and Impact

With a presence in various regions, including Australia, New Zealand, the Middle East, and Africa, IQVIA’s global footprint allows it to drive healthcare innovations worldwide.

AI and Technology Integration

The company is at the forefront of integrating AI and other technologies in healthcare. Their Healthcare-grade AI promises precision, speed, scale, trust, and reliability, essential for advancing health and improving patient outcomes.

Extensive, reliable healthcare data enhances market research quality.
Utilizes AI and machine learning for advanced healthcare insights.
Specialized focus yields a deep understanding of healthcare dynamics.
Broad international presence enables diverse and large-scale studies.
Offers advanced tools for insightful healthcare data analysis.
Advanced tools can be challenging to use without training.
Handling sensitive health data raises privacy and security issues.

Our Review of IQVIA

IQVIA, a prominent player in the healthcare and life sciences industry, presents a mixed bag of strengths and weaknesses. On the positive side, we appreciate IQVIA’s extensive expertise in data analytics and healthcare consulting.

Their comprehensive research and analysis have undoubtedly driven valuable insights and innovations in the sector. Moreover, their global presence allows for diverse perspectives and access to critical healthcare data.

However, we must also acknowledge some shortcomings. IQVIA’s services can be prohibitively expensive for smaller organizations, limiting accessibility. Additionally, the sheer volume of data can sometimes lead to information overload, making it challenging to extract actionable insights.

ICON is a prominent company in the field of clinical research, playing a significant role in advancing medical science. They specialize in designing and conducting clinical trials for new medicines and treatments.

The work of ICON is crucial because they help determine the safety and effectiveness of these potential medical breakthroughs. They are considered one of the best in clinical research due to their high standards of accuracy, reliability, and ethical practices.

ICON’s expertise ensures that the clinical trials they manage are conducted efficiently and effectively, leading to faster approval of new treatments. This directly impacts patient care, as it allows quicker access to new, potentially life-saving medicines.

In essence, ICON’s contribution is vital in driving forward medical innovations.

Founding Team: John Climax and Ronan Lambe
Founding Year: 1990
Company Size: 41,160

Features of ICON

Here are some of the key features of ICON in clinical research:

Diverse Clinical and Scientific Operations

ICON offers a wide range of clinical and scientific operations services, ensuring comprehensive support for various aspects of clinical trials. This includes everything from study design to execution and data analysis.

Decentralized Clinical Trial Solutions

They provide end-to-end services, operational models, and technology to deliver customized solutions for decentralized clinical trials. This approach is increasingly important in today’s clinical research landscape, offering flexibility and efficiency.

Specialized Therapeutic Areas

ICON has expertise across multiple therapeutic areas including cardiovascular, central nervous system, endocrine & metabolic disorders, infectious diseases, internal medicine & immunology, oncology, and more. This broad expertise allows them to handle a wide range of clinical research projects.

Innovative Solutions for Biotech

ICON provides full-service outsourcing and flexible support customized to the specific needs of biotech companies. This includes due diligence and asset valuation, which are critical for biotech firms navigating the complex landscape of drug development.

Advanced Medical Imaging Solutions

Their expert medical imaging solutions support all stages of clinical research, improving decision-making, increasing efficiency, and reducing trial costs.

Decades of expertise ensure high-quality clinical research.
Offers wide-reaching capabilities for multi-regional clinical studies.
Deep understanding of global regulations enhances compliance and efficiency.
Invests in new technologies for more efficient trial processes.
Broad range of specialties contributes to comprehensive service offerings.
Managing multi-regional trials can lead to logistical challenges.
Rapid growth may strain resources and affect service quality.

Our Review of ICON

When we researched ICON, we found both commendable aspects and areas for improvement. On the positive side, we appreciate their commitment to clinical research and their global presence, which allows for diverse study options. Their experienced team and advanced technology contribute to reliable data collection and analysis.

However, there are some drawbacks to consider. We have noticed occasional delays in project timelines, which can be frustrating. Additionally, the cost of their services tends to be on the higher side, making it a potential barrier for smaller research endeavors.

Parexel is a globally recognized company in clinical research, known for its important role in developing new medical treatments. They are one of the biggest clinical research organizations. Parexel conducts clinical trials, crucial steps in testing the safety and effectiveness of new drugs.

The work of Parexel is essential because it bridges the gap between medical research and the availability of new treatments to patients. One of the reasons they stand out as one of the best in this field is their rigorous approach to research.

Their commitment to quality and their global network also enables diverse and large-scale studies, setting them apart from others in the field. These strengths allow Parexel to deliver reliable and valuable data, accelerating the process of bringing new, effective medicines to the market.

Simply put, Parexel is a key player in transforming medical research into real-world health solutions.

About Parexel

Founding Team: Josef von Rickenbach and Anne B. Sayigh
Company Size: 18,900

Features of Parexel

Parexel, a global biopharmaceutical services organization, offers a range of features in clinical research. Here are some key aspects of their approach:

Patient-Centric Approach

Parexel emphasizes a patient-first strategy in their clinical trials. This approach results in deeper and more relevant insights for trial design and execution. This ensures that the trials are more aligned with patient needs and experiences.

Innovative Trial Designs

Parexel employs innovative trial designs to optimize trials for maximum impact. This includes advanced modeling and simulation to predict drug effects ahead of time, which can save time, money, and resources.

Regulatory Compliance and Market Access

Parexel designs studies and endpoints with market access in mind, ensuring that they satisfy global regulations. This approach helps in getting treatments to patients safely and quickly.

Patient Advocacy and Engagement

The company includes patient advocates in their council, using their experiences to improve trial designs. This inclusion demonstrates their commitment to understanding and incorporating patient perspectives in clinical research.

Focus on Speed and Precision

Parexel aims to design neuroscience trials with speed and precision, utilizing the right experts and specializations. This focus is crucial in delivering effective treatments on time.

Provides advanced technology and analytics for efficient data management.
Extensive network provides global insights with regional knowledge.
Expertise in navigating complex regulatory environments worldwide.
Broad experience across various therapeutic areas ensures versatile solutions.
Focuses on patient engagement for more effective trial outcomes.
Rapid expansion can lead to challenges in resource management.
Concentration in specific areas could pose risks in market shifts.

Our Review of Parexel

Parexel is a notable player in the field of clinical research and pharmaceutical services. We’ve thoroughly analyzed their offerings and found both strengths and areas that need improvement.

On the positive side, Parexel excels in its commitment to innovation and technology. We appreciate their continuous efforts to simplify clinical trials and drug development processes, making them more efficient.

However, we also noticed some downsides. Communication with clients could be more transparent, with clearer updates on project progress. Additionally, there’s room for improvement in terms of ensuring consistency in service quality across different projects.

Other 12 Companies of Clinical Research

In the world of clinical research, beyond the well-known names, there are 12 other companies making significant contributions. Let’s explore their vital role in advancing healthcare.

1. Syneos Health

Syneos Health helps develop medicines by managing clinical trials for new drugs. They’re essential because they ensure medicines are safe and effective. Syneos Health stands out in clinical research for its comprehensive services and global reach, making drug development smoother and faster.

About Syneos Health

Founding Team: Colin Shannon
Founding Year: 1980
Company Size: 28,000

PPD is a group that tests new drugs to see if they’re good and safe. This is crucial for getting new treatments to people. They stand out for their thorough research and global reach.

Founding Team: Fred Eshelman
Founding Year: 1985
Company Size: 40,000+3

Labcorp does important tests and research for health. They’re needed because they help find out if new treatments are good. They’re among the best for their big labs and fast results.

About Labcorp

Founding Team: Matthew Benger
Founding Year: 1978
Company Size: 75,5000

Medpace focuses on making sure new health treatments are safe. This is key for better medicine. They’re a top choice because of their focus on quality and detail in research.

About Medpace

Founding Team: August Troendle
Founding Year: 1992
Company Size: 5,400

5. Charles River Laboratories

Charles River Laboratories tests drugs and does research to help pets and people stay healthy. They’re essential for safe, new treatments. Their expertise makes them a leader in the field.

About Charles River Laboratories

Founding Team: Henry Foster
Founding Year: 1947
Company Size: 21,400

6. PRA Health Science

PRA Health Science works on finding out if new medicines are safe. This helps everyone get better treatments. They’re known for their excellent research and care in studies.

About PRA Health Science

Founding Year: 1976
Company Size: 17,000+

7. AdvanCell

AdvanCell specializes in new treatments, checking if they’re safe and working. Their work is vital for progress in medicine. They’re recognized for their innovation in research.

About AdvanCell

Founding Team: Andrew Adamovich

Dynata gathers data for health studies. They’re needed for understanding what works in healthcare. They’re a top name for their accurate and wide-reaching data collection.

About Dynata

Founding Team: Mike Petrullo
Founding Year: 1940
Company Size: 5000-10000

Covance helps with drug tests and research to fight diseases. Their role is key for new treatments. They’re celebrated for their comprehensive services and global impact.

About Covance

Founding Team: Fred Cummings
Founding Year: 1981
Company Size: 50,000

MedNet provides software for managing clinical trials. This helps in making research easier and faster. They’re among the best for their tech solutions in research.

About MedNet

Founding Team: John “Rob” Robertson
Founding Year: 1996
Company Size: 51-200

11. Fisher Clinical Services Inc.

Fisher Clinical Services Inc. manages the logistics of clinical trials, ensuring that treatments are tested efficiently. Their work is crucial for the progress of medicine, and they are renowned for their reliability and global network.

About Fisher Clinical Services Inc.

Founding Team: John Pickering
Founding Year: 1989

12. Worldwide Clinical Trials

Worldwide Clinical Trials conducts essential research to evaluate new medical treatments. Their work is critical for advancing healthcare. They are distinguished by their global expertise and commitment to innovation in clinical research.

About Worldwide Clinical Trials

Founding Team: Neal Cutler
Founding Year: 1986
Company Size: 3,147

What To Consider When Choosing the Best Clinical Research Companies?

Choosing the right clinical research company (CRC) is crucial for the success of any clinical trial. Here’s a detailed guide on what to consider:

Expertise and Specialization

Always ensure the CRC has expertise in your specific therapeutic area. Companies with experience in similar drug trials or medical devices can better navigate the complexities of your project.

Regulatory Compliance

The CRC must adhere to regulatory guidelines like FDA (US) , EMA (Europe), and others. Check their track record in meeting these standards to avoid compliance issues.

Reputation and Track Record

You should research the company’s history. Look for testimonials, case studies, and reviews from past clients. A company with a strong reputation is likely to deliver quality results.

Project Management Capabilities

Effective project management is key. Assess their ability to manage timelines, budgets, and communication. A CRC that provides transparent, regular updates is preferable.

Patient Recruitment Strategies

Patient recruitment can be challenging. Evaluate their strategies for participant recruitment and retention. Consider their demographic reach and methods for ensuring a diverse participant pool.

Data Management and Analysis

The CRC should have strong systems for data collection, management, and analysis. Ask about their use of Electronic Data Capture (EDC) systems and how they handle data security and confidentiality.

Cost and Financial Terms

Get a clear understanding of the cost structure. Consider the value for money rather than just the lowest cost. Ensure there are no hidden fees and clarify what is included in the quoted price.

How Heartbeat AI Can Help You Get the Best List of Clinical Research Organizations?

Heartbeat AI, with its advanced features, can significantly assist in identifying the best list of clinical research organizations (CROs). Here’s how its various features contribute to this process:

Data Analysis and Processing

Heartbeat AI excels in analyzing vast amounts of data. When it comes to selecting CROs, it can process and analyze information from numerous sources, including past performance records, clinical trial reports, and regulatory compliance data. This thorough analysis helps in identifying CROs with a proven track record of success and reliability.

Machine Learning Algorithms

These algorithms enable Heartbeat AI to learn from historical data and improve its recommendations over time. By understanding trends and patterns in the successful execution of clinical trials, it can better predict which CROs are likely to meet your specific needs.

Predictive Analytics

Heartbeat AI uses predictive models to forecast future trends and outcomes based on historical data. This can be invaluable in predicting the success rate of CROs in upcoming projects, thus aiding in making more informed choices.

Customization and Personalization

The AI can be customized to your specific requirements. If you’re focusing on a specific therapeutic area or clinical trial phase, Heartbeat AI can prioritize specialized CROs in these fields.

Real-time Data Updates

The healthcare and pharmaceutical landscapes are constantly changing. Heartbeat AI’s ability to integrate and analyze real-time data ensures that the recommendations are based on the most current information available.

Integration with External Databases

Heartbeat AI can integrate with various external databases and platforms. This enables it to pull in comprehensive information about CROs from diverse sources, enhancing the accuracy of its recommendations.

Claim $500 of Free Data

Summing up, we’ve explored the best clinical research companies, diving into their features, strengths, weaknesses, and more. Clinical research is vital in healthcare; it’s key for advancing medical knowledge and developing new treatments.

With this guide, you’re equipped to find the right clinical research company that meets your specific needs. Whether it’s for innovative therapies, drug development, or medical advancements, choosing the right partner is crucial. This guide serves as a valuable resource to help you make an informed decision in the complex world of clinical research.

Frequently Asked Question

What services do companies of clinical research offer.

Clinical research organizations offer a wide range of services, including protocol development, patient recruitment, data collection and analysis, regulatory compliance, and more.

What is the role of a clinical research coordinator?

A clinical research coordinator is responsible for managing various aspects of a clinical trial, including patient recruitment, data collection, and ensuring compliance with protocols.

What is informed consent in clinical research?

Informed consent is the process by which participants in a clinical trial are fully informed about the study’s purpose, risks, and benefits. They voluntarily agree to participate based on this information.

Enter your account information

Access 11m+ Healthcare providers
100% Risk Free Trial
No credit card required

Enter your phone number

28 Biotech Companies Bolstering Life Sciences

While biotech has long been a vital component of the global tech market, this pivotal sector has seemingly reached new heights over the past decade. And although organizations around the world have tried to rule the life sciences space, the United States remains the undisputed biotech leader.

Biotech Companies to Know

Flatiron health.

According to reports , the nation’s life sciences sector alone generates over $112 billion in revenue. In light of biotech’s mounting economic impact, it’s no surprise that tech hubs across the country are witnessing a surge in life sciences companies , bolstering the nation’s status as a biotech epicenter.

Over the past couple years, the importance of the biotech industry has been even further amplified, as the world raced to create a COVID-19 vaccine.

While focus has been on combating COVID-19, the country’s biotech leaders continue to dedicate themselves to addressing other pressing medical issues. Backed by teams of world-renowned scientists and technologists, these organizations are addressing challenges across the healthcare spectrum. Whether they’re formulating new cancer treatments or harnessing the power of human genetics, the nation’s biotech companies are making a monumental impact on the future of medical research and drug discovery.

We’ve rounded up the top biotech companies to give you a glimpse into the burgeoning life sciences sector.

Novo Nordisk

Location: Bagsværd, Denmark

Novo Nordisk has been around since the 1920s, and today focuses on developing treatments and pharmaceuticals for chronic illnesses such as diabetes and hemophilia. The company has roughly 860 research and development employees working in the United States and is conducting clinical trials in more than four dozen countries.

Location: Boston, Massachusetts

Biotech firm Asimov is a genetic design company. It uses machine learning, computer-aided design and a niche of biology known as synthetic biology — a field that redesigns existing organisms for new uses — to genetically engineer therapeutics like biologics and gene therapies. Asimov markets a platform that includes host cells, a genetic parts library, technical guides and design software for creating genetic systems in various types of cells.

Location: Menlo Park, California

GRAIL is on a mission to detect cancer at earlier stages so that it can be more easily cured. The company focuses on seeking cancer signals in the blood, guided by the belief that tumors release cell-free nucleic acids into the bloodstream, which are thought to be a direct measure of cancer and can potentially be detected before the onset of symptoms. GRAIL intends to foster a deeper understanding of cancer biology through its high-intensity sequencing assays and population-scale clinical studies.

Schrödinger, Inc.

Location: Cambridge, Massachusetts

Schrödinger is powering drug research with its computer simulations platform. Founded in 1990, the company employs physics-based methods to evaluate chemical matter and compounds before synthesis. As a result, researchers should see faster lead discoveries, accurate property descriptions and access to large-scale molecular exploration. The company also provides integrated data and visualization tools

Location: San Diego, California

Illumina seeks to make “genomics more useful for all, for a better understanding of human health .” The company develops products for cancer research, reproductive health, genetic and rare diseases and microbial genomics.

Location: Lexington, Massachusetts

Founded in the 18th century, Takeda is a global pharmaceutical company with a strong emphasis on research and development. The company focuses its research in several areas: oncology, rare diseases, plasma-derived therapies, vaccines, neuroscience and gastroenterology. In the U.S. alone, Takeda has created over 50 products and service programs that benefit patients and physicians.

Viome Life Sciences

Location: Bellevue, Washington

Viome Life Sciences believes microbial and human gene expression are altering how biological activities and human health are connected. The company uses an mRNA platform to digitize human data to prevent, diagnose and treat chronic illnesses and diseases. Through the platform, consumers can receive personalized recommendations — like dietary restrictions and exercise plans — on how to live a healthy life.

Location: San Francisco, California

Invitae provides genetic testing services, the Invitae Digital Health platform to coordinate patient care, biopharma partnerships. Its products have applications for oncology, reproductive health, pediatrics, cardiology and pathology.

Variant Bio

Location: Seattle, Washington

Variant Bio uses innovative sequence technology and studies the genetics of individuals with “exceptional health-related traits.” The company’s goal: to transform drug development as we know it today and, ultimately, find better ways to treat diseases.

Benchling is dedicated to speeding up life sciences research through its suite of unified applications, which are housed within the company’s life sciences research and development cloud. The cloud serves as a platform for centralizing and standardizing all R&D data, enabling users to track every workflow, automatically interlink related data and easily and quickly export data. Benchling’s applications can be used for the research of antibodies, cell therapy, proteins and peptides, gene therapy, vaccines and more.

Location: San Mateo, California

Helix created an end-to-end genomics platform in an effort to enable health systems, life sciences companies and payers to advance genomic research. The company’s platform allows users to deliver actionable genetic insights and conduct large-scale genetic analyses. Helix’s Exome+ assay is designed to facilitate the discovery and analysis of rare and novel variants, genome-wide imputation, polygenic risk score calculation, ancestry inference and more.

Charles River Laboratories

Location: Wilmington, Massachusetts

Charles River Laboratories ’ focus is on the quick, efficient and safe discovery and development of drugs and therapeutics. The company provides products and services that take its clients from the basic research stage to clinical development and commercialization. Its customers come from the pharmaceutical, biotech, agrochemical, and academic sectors.

Location: Rahway, New Jersey

Merck ’s efforts center around biopharmaceutical research for preventing and treating disease in people and animals with a focus on oncology, vaccines, infectious diseases, COVID-19, cardio-metabolic disorders and discovery and development.

Recommended Reading 40 AI in Healthcare Examples Improving the Future of Medicine

Location: New York, New York

Flatiron Health aims to reinvent cancer care by learning from the experiences of cancer patients. The company’s Flatiron HC platform can help providers with administrative tasks, matching patients to clinical trials they’re eligible for and accessing patient information whenever or wherever they need.

Imagen Technologies

Imagen Technologies is dedicated to making diagnostic care more accessible while eliminating errors in radiology. The company’s FDA-cleared Computer Assisted Detection and Diagnosis software applies AI technology to medical image analysis in an effort to improve patient outcomes.

Location: Chicago, Illinois

CancerIQ is dedicated to helping providers use genetic information to predict and prevent disease. The company provides user-friendly screening tools that allow healthcare providers to offer patients easy risk assessment questionnaires in waiting rooms and track patient outcomes over time to keep them engaged and informed. CancerIQ’s screening solution enables providers to replace long paper forms and quickly identify patients eligible for genetic counseling, genetic testing or an MRI.

Location: Palo Alto, California

BridgeBio works in medicine development for patients who have genetic diseases and cancers with clear genetic drivers. The company’s partners have included St. Jude Children’s Research Hospital and The University of Texas MD Anderson Cancer Center.

Location: Chicago, Illinois

Neurocern aims to leverage neuroinformatics and data analytics to improve the quality of life and longevity of neurological patients. The company’s technology is designed to identify different types of dementia more effectively than other forms of diagnosis. Neurocern is guided by the belief that analytics can connect siloed markets in new ways to improve long-term care outcomes and ultimately find cures for neurodegenerative diseases.

Location: Foster City, California

Notable ’s platform aims to dramatically reduce the cost and time associated with the traditional drug development process. Powered by machine learning, automation and high-throughput flow cytometry, the company’s precision medicine platform is capable of determining which drugs or drug combinations would be most effective for specific types of cancers. Notable’s mission is to change the way clinicians and prescribers select treatments for the millions of individuals suffering from hematological cancers.

Recommended Reading Radar Can Detect Your Heartbeat. Really.

Atomwise developed deep learning technology for the discovery of structure-based small molecule drugs. The company’s AtomNet technology utilizes a statistical approach in order to extract insights from millions of experimental affinity measurements and thousands of protein structures to predict the binding of small molecules to proteins. Atomwise’s technology removes some of the physical barriers that previously limited the success of drug discovery, and has the ability to analyze a very large chemical space to identify a small subset with high specificity for synthesis and testing.

Location: Austin, Texas

Natera is a genetic testing and diagnostics company dedicated to changing how doctors and patients manage genetic disease. The company’s solutions include personalized cancer care management, health assessments for transplant patients and women’s health testing. Natera aims to deliver technology and finely-tuned workflows that drive superior clinical and analytics performance.

ATX Therapeutics

ATX Therapeutics is dedicated to helping people more easily manage chronic health conditions such as cancer and heart disease. The company offers evidence-based digital therapeutics intervention programs, which are based on individual patients’ health history, needs and abilities. ATX Therapeutics’ programs are designed to be integrated into patient lifestyles and provider workflows to deliver a fully integrated healthcare experience.

Location: Greenwood Village, Colorado

VieCure aims to make genomic-based cancer care more accessible for patients and providers. The company’s platform operates as a point-of-care clinical decision support system that combines clinical knowledge with patient data to help oncologists generate personalized treatment plans and manage patients’ care. VieCure intends for its platform to serve as a value-added extender for every oncologist, nurse, therapist and clinical researcher.

Paige seeks to transform the diagnosis and treatment of cancer with its AI-native digital pathology ecosystem. The company’s AI suite is intended to provide data-driven insights to pathologists, clinicians and pharmaceutical teams. Paige’s aim is to propel cancer care with more powerful and efficient tools for diagnosis, treatment selection and drug development.

Location: Santa Monica, California

Quantgene aims to transform the future of medicine by unlocking the deep human genome. The company’s platform combines deep genomic sequencing and AI to detect mutational patterns of disease down to a single molecule, thus helping inform early cancer detection, prediction of disease onset and non-invasive treatment monitoring. Additionally, Quantgene’s Serenity Medical Intelligence is intended to extract vital health data from patients’ DNA so they can help protect themselves from chronic diseases, drug interactions and lifestyle risks.

Location: Cambridge, Massachusetts

Moderna is a pharmaceutical company working to use mRNA technology to develop medicines, vaccines and therapeutics. Infectious diseases, immuno-oncology, cardiovascular disease and autoimmune diseases have been among Moderna’s areas of focus.

Recommended Reading Topv 16 Machine Learning Companies in Healthcare

Strata Oncology

Location: Ann Arbor, Michigan

Strata Oncology is a genomic testing company working on precision medicine for cancer patients. The company’s StrataNGS genomic profiling test is effective for smaller tumor tissue samples compared to other tests, making testing that can inform immunotherapy decisions more accessible to patients with advanced solid tumors.

Myriad Genetics

Location: Salt Lake City, Utah

Myriad Genetics aims to provide accurate genetic insights to improve disease diagnosis, treatment and prevention. The company offers multiple testing options, including MyRisk hereditary cancer risk testing and Prequel prenatal screening.

Great Companies Need Great People. That's Where We Come In.

Top 17 Clinical Research Organizations (CRO) in 2023

In clinical research and treatment development, clinical research organizations (CROs) are frequently a sponsor’s most important partner and ally.

Depending on the nature of the clinical trial, and your existing capabilities as a sponsor to run the trial, the CRO company of your choice will typically be responsible for facilitating most of the micro and macro processes that go into designing and running a successful clinical trial.

When contracting a CRO to help you with your trial, you are transferring over a large portion of responsibility into the hands of your clinical research partner. The CRO of your choice will have the responsibility to control a variety of factors and processes of a clinical trial, and depending on their expertise, team structures, service offerings, internal resources and many other capabilities.

Your ability to find and contract a top CRO company that is the right fit for your unique trial will be a determinant of whether or not you will be able to operate a high-quality clinical trial that meets your expected timelines, budget and delivers a top-notch patient experience.

At ClaraHealth (a patient-centric recruitment acceleration platform) , we have put together an extensive list of the top CRO companies in the US and around the world.

This is not a cro rankings list, but rather a compiled list of some of the top clinical research organizations around the world. We have highlighted their strengths and core service offerings to make it easier for you to find the right fit clinical research partner.

In addition, we’ve put together a list of 9 fundamental questions to ask the prospective clinical research organization , which will help you to save time and ensure a right fit in picking the CRO.

Formerly known as Quintiles and IMS Health, IQVIA is one of the largest CROs in the world, with a large range of service offerings to help advance clinical research.

The company was founded in North Carolina in 1982, and has since grown to over 88,000 employees in more than 100 countries.

Some clinical trial solutions offered by IQVIA include:

Assistance with protocol design
Design of phase 1 clinical trials
Assessment and improvement of phase 2 and 3 clinical trials
Site identification & selection
Patient recruitment
Access to global laboratories via their wholly owned subsidiary Q2 Solutions

Parexel is a global clinical research organization that was founded in 1982, and specializes in conducting clinical studies on behalf of its pharmaceutical partners in order to accelerate and ensure the drug approval process of up-and-coming potential treatments. It currently operates in more than 50 countries, and is run by more than 18,000 employees around the world.

The company has a wide range of service offerings, covering nearly every type of clinical trial service to assist sponsors in running successful clinical studies.

Some clinical trial solutions offered by Parexel include:

Clinical trial design and development for early phase, phase 2 & 3, and late phase clinical trials
Clinical data management
Decentralized clinical trials
Clinical supply chain management
Medical writing
Regulatory affairs consulting
Pharmacovigilance

3. PRA Health Sciences

PRA Health Sciences is one of the largest contract research organizations in the world. Founded in 1976 under the name “Anti-Inflammatory Drug Study Group”, the company was renamed to PRA in 1982. PRA Health Sciences employees more than 17,000 people, and provides coverage to more than 90 countries.

In 2021, PRA Health Sciences was acquired by the Ireland-headquartered global CRO leader ICON, which is also reviewed in this list.

Some clinical trial solutions offered by PRA Health Sciences include:

Decentralized Clinical Trials Platform
Protocol Consultation & Study Design
Onsite Support services
Customized Solutions for Biotech (such as asset valuation, regulatory strategy, engagement and support, drug development strategy and funding solutions)
Clinical Diagnostics
Site Commercial Solutions
PRA’s Laboratories for Drug Development

Headquartered in Ireland, ICON was founded in 1990 in Dublin by co-founders John Climax and Ronan Lambre. The company has since grown to be one of the largest CROs in the world. As of September 2020, the company employs more than 15,000 people in 94 locations and across 40 countries.

ICON offers clinical research services which include consulting, clinical development and commercialization across a wide range of therapeutic areas.

In 2021, ICON acquired PRA Health Sciences, which is another CRO and global leader in clinical research services.

Some clinical trial solutions offered by ICON:

Commercial Positioning
Early Phase
Functional Services Provision
Laboratories
Language Services
Medical Imaging
Real World Intelligence
Site & Patient Solutions
COVID-19 Clinical Operations

5. Syneos Health

Formerly known as InVentiv Health Incorporated and INC Research, Syneos Health is a publicly listed and global contract research organization. The company is based in Morrisville, North Carolina, and specializes in assisting companies with late-stage clinical trials. Syneos Health currently employs more than 25,000 people, and has offices across 91 locations.

In early 2018, INC Research was acquired inVentiv Health, and the merged company was named Syneos Health.

Some clinical trial solutions offered by Syneos Health include:

Decentralized Clinical Trials Solutions
Bioanalytical Solutions
Phase II-III/Phase IIIb-IIIV
Medical Device Diagnostics
Clinical Data Management
Clinical Project Management
Clinical Monitoring
Drug Safety & Pharmacovigilance
Site and Patient Access

6. Labcorp Drug Development (Formerly Covance)

Formerly known as Covance and renamed to Labcorp Drug Development in early 2021, this CRO is one of the largest contract research organizations in the world. The company claims to provide the world’s largest central laboratory network, and has been rated as one of the best places to work for LGBTQ+ equality by the Human Rights Campaign organization in 2018 to 2021. Currently, Labcorp employs over 70,000 people and is able to support clinical research efforts in almost 100 countries around the world.

Some clinical trial solutions offered by Labcorp Drug Development include:

Preclinical Services
Clinical Trials
Clinical Trial Laboratory Services
Post-Marketing Solutions
Medical Devices
Data & Technology

Also known as Pharmaceutical Product Development, PPD is a large global contract research organization headquartered in Wilmington, North Carolina. Started as a one-person consulting firm in 1985, PPD has grown to over 27,000 employees worldwide, and provides a wide range of clinical research services to pharmaceutical and biotech companies.

Some clinical trial solutions offered by PPD include:

Clinical Development
Early Development
Peri- and Post-Approval
PPD Biotech
PPD Laboratories
Product Development and Consulting
Site and Patient Centric Solutions

8. Fisher Clinical Services

Part of Thermo Fisher Scientific, Fisher Clinical Services is a global clinical research organization with headquarters in Center Valley, Philadelphia.

The company has been in the business of clinical supply chain management for over 20 years, and is focused exclusively on working with the packaging and distribution requirements of clinical trials across the globe.

Some clinical trial solutions offered by Fisher Clinical Services include:

Biologistics Management
Cell & Gene Therapy
Clinical Ancillary Management
Clinical Label Services
Clinical Trial Packaging & Storage
Clinical Supply Optimization Services
Cold Chain Management & Expertise
Direct-to-Patient
Distribution & Logistics
Strategic Comparator Sourcing
Public Health Research

Established in 1997 under the name Kiecana Clinical Research, KCR is a full-service contract research organization that provides a variety of services for clinical monitoring, safety & pharmacovigilance, clinical project management, quality assurance and regulatory affairs.

KCR operates globally, and has offices in North America, Western Europe, Central Europe and Eartern Europe. The company currently employs more than 700 staff.

Some clinical trial solutions offered by KCR include:

Trial Execution

10. Medpace

Founded in 1992 and based in Cincinnati, Ohio, Medpace is a midsize clinical contract research organization. The company has operations in over 45 countries, and employs over 2,800 people. Medpace provides support services for Phase I-IV clinical trials for pharmaceutical and biotechnology companies, which include central laboratory services and regulatory services.

Some clinical trial solutions offered by Medpace include:

Biostatistics and Data Sciences
Clinical Trial Management
Drug Safety and Pharmacovigilance
Medical Writing
Quality Assurance
Regulatory Affairs
Risk-Based Monitoring
Medpace Laboratories

11. Clintec

Now in business for over 22 years, Clintec is a medium-sized global contract research organization for pharmaceutical, biotech and medical device industries, with large expertise in oncology and rare diseases.

The company provides the flexibility and agility of a smaller-sized CRO, while also having a wide global coverage that large CRO companies are known for. Clintec is based in more than 50 countries, and was acquired by the leading global CRO IQVIA in late 2018.

Some clinical trial solutions offered by Clintec include:

Project Management
Data Management
Biostatistics
Global Feasibilities
Patient Recruitment & Retention

12. Worldwide Clinical Trials

Bringing over 30 years of experience to the clinical research market, Worldwide Clinical Trials is a leading medium-sized global contract research organization. Founded by physicians with a dedication and commitment to advancing medical research, Worldwide Clinical Trials was the first customer-centric CRO.

Currently the company has coverage in more than 60 countries, and has extensive experience in a wide range of therapeutic areas, including central nervous system, metabolic, cardiovascular, oncology, rare diseases and general medicine.

Some clinical trial solutions offered by Worldwide Clinical Trials include:

Bioanalytical Lab
Early Phase Development
Clinical Phase IIB-II Clinical Trials
Phase IIIB-IV Clinical Trials
Trial Management Technologies

Named #1 CRO in the world for operational excellence at the 2021 CRO Leadership Awards, CTI Clinical Trial And Consulting Services is a medium-sized global contract research organization that has been serving pharmaceutical companies since 1999.

Based in Covington, Kentucky, CTI has offices around the world in more than 60 countries, with coverage in North America, Europe, Latin America, Middle-East, Africa, and Asia-Pacific regions.

Some clinical trial solutions offered by CTI include:

Feasibility
Regulatory Affairs Study Start-Up
Medical Monitoring
Safety & Pharmacovigilance
Clinical Services

14. Wuxi AppTec

Founded in 2000 as WuXi PharmaTech in the city of Wuxi, China, Wuxi AppTec has grown from a single laboratory into a leading global contract research organization with more than 28,000 employees, including 23,000 scientists and more than 30 research & development and manufacturing sites around the world.

With offices in Asia, U.S, Europe and the Middle East, the company is able to provide coverage to more than 30 countries around the world.

Some clinical trial solutions offered by Wuxi AppTec include:

Small Molecule Drug R&D and Manufacturing
Cell Therapy and Gene Therapy
Drug R&D and Medical Device Testing
Clinical Services (Phase I-IV)

15. Advanced Clinical

Founded in 1994 and based out of Deerfield, Illinois, Advanced Clinical is a midsize and full-service CRO that helps sponsors with running clinical trials. The company employs more than 700 staff, and offers a wide variety of services across many therapeutic areas. Advanced Clinical has global representation in over 50 countries around the world.

Some clinical trial solutions offered by Advanced Clinical include:

eTMF & Document Management
Global Medical Services
Quality & Validation

16. Pharm-Olam

Pharm-Olam is a leading midsize CRO with global headquarters located in Houston, Texas and its European headquarters in Bracknell, United Kingdom. The company employs more than 800 staff, and has 25 offices around the world, with a global coverage in more than 60 countries.

The company has therapeutic expertise in 5 areas, including Rare & Orphan Disease, Infectious Disease & Vaccine, Oncology-Hematology, Allergy and Autoimmune.

Some clinical trial solutions offered by Pharm-Olam include:

Study Feasibility
Site Activation
Patient Recruitment
Medical Affairs
Compliance & Training
Clinical Monitoring & Operations

17. Clinipace

Founded in 2003 and based out of Morrisville, North Carolina, Clinipace is a global midsize full-service CRO with a focus on solution customization for clinical trials. The company has a large global coverage in more than 50 countries, and has offices in North America, South America, Europe and Asia-Pacific regions.

Clinipace’s therapeutic focus areas include Oncology, Nephrology and Urology, Rare Disease, Gastroenterology and Women’s Health. The company also has complete therapeutic expertise in Infectious Disease & Vaccines, Cardiology, CNS, Immunology, and Respiratory.

Some clinical trial solutions offered by Clinipace include:

Clinical Analytics
Clinical Technology and Ecosystem
Functional Service Partnership (FSP)
Regulatory & Strategic Product Development

9 Fundamental Questions To Ask A Top CRO Company Before Signing The Contract

1. which services does the cro provide.

CROs offload a lot of operational tasks from trial sponsors, which can touch any component of clinical trial operations. From formulating an overall study strategy and implementing technologies to support the operational processes of the trial, to picking and identifying sites, and supporting patients during the trial, the range of clinical services offered by a CRO tends to be vast and inclusive of all the typical services and support you will require for running a successful clinical trial.

However, not all CROs are the same in their service offerings, or are able to offer the same depth of capability within a seemingly same clinical trial support process. For this reason it is important to understand exactly which kind of clinical services and support you are looking to receive from the prospective CRO when running your clinical trial.

While services such as clinical monitoring and clinical trial management are offered by the majority of CROs, the specific needs of each trial are unique, and for this reason it is important to first identify what will be the unique services your trial requires. Completing this internal analysis first will help you to understand the extent to which a potential CRO partner will be able to provide all of these services.

Some CROs specialize in specific clinical trial functions which the company may label as a “core services”, in which case this is a sign the company will have more expertise, experience, and will be set up in a way to maximize their capabilities in providing support for these services compared to other services that the CRO offers.

For example, a CRO may include patient recruitment as part of its “core services”, which implies that they are highly skilled in and have the necessary infrastructure to design and implement a high-quality patient recruitment strategy.

Clara Health CRO Support Services: At Clara Health our specialty services include technology-augmented digital and patient advocacy recruitment, as well as patient support via our signature patient recruitment platform, which we use to upgrade clinical trials and deliver results sponsors look for in their recruitment and retention campaigns.

At Clara, we work alongside CROs to supplement and support clinical trials with modern and personalized capabilities that CROs do not typically have the bandwidth, corporate structure or infrastructure to support.

If you would like to learn more about exactly how our platform can upgrade your unique trial, feel free to book a Free 30 Minute Consultation Session Here with one of our in-house experts.

2. What Related Experience Does The CRO Have?

It is helpful to ask the prospective CRO company if they have any relevant experience in running clinical trials that would be an asset in designing and running your study. Previous experience in a related therapeutic area or in running a trial with a similar design allows CROs to have a deeper understanding into potential opportunities and challenges, increasing the likelihood of your clinical study being successful.

For example, if a sponsor is planning to run a trial in oncology, for the purpose of site identification and selection it would be valuable to partner with a CRO vendor that has expertise in this area, as they likely already have a good understanding of which sites will lead to optimal results.

However, it is also important to consider all factors when selecting a CRO vendor and not to rely on therapeutic experience as the sole qualifier for whether or not a potential CRO is a fit for your trial. While previous experience is beneficial, some sponsors close themselves off from working with vendors that have not worked in their therapeutic area, which significantly limits options when choosing a CRO partner that is truly a good fit for their clinical study.

This can impact the end result of your clinical study, as sponsors that are not successful in choosing a CRO vendor that is the right overall fit may face difficulties if the needs of their clinical study aren’t being properly met.

Clara Health: We have worked to provide support for clinical trials across a wide range of therapeutic areas and trial designs. Our specialty is filling in the gaps that CROs traditionally did not have to think about, which include digital patient recruitment, patient advocacy recruitment, and technology-augmented patient support.

Additionally, we are constantly building our proprietary data and running tests in a variety of therapeutic areas. These research efforts allow us to have a detailed understanding of the expected level of difficulty when recruiting particular patient populations, as well as allow us to predict with accuracy which segments of the targeted population will be likely to qualify in a particular study.

3. What Are The Communication Workflows & Expectations For Performing And Delivering Contracted Services?

It is important that you clarify what the expectations for communication will be between your prospective CRO vendor and your internal teams, as you will most likely be working with the CRO of your choice for the entire duration of your clinical trial.

There are a vast variety of factors and success determinants for a clinical trial, which are continuously undergoing change as the study unfolds. For this reason, it is recommended that you work with a CRO that is proactive in their communication, so that you are kept up to date with information about important changes as your clinical trial progresses.

A vendor that is proactive rather than reactive in their communication and approach to dealing with arising issues is one of the most important qualities in CRO. Challenging situations will naturally arise, and the promptness with which they are taken care of will significantly impact your clinical trial’s degree of success. Therefore, seeking a vendor that is able to match the standard of communication that you as a sponsor would like to experience throughout the duration of your partnership is one of the most critical steps in determining which CRO is the right fit for your clinical trial.

We’ve included a few additional questions pertaining to the communication structure and reporting expectations that you can ask a prospective CRO vendor to determine the degree of fit in this particular category:

Communication Expectations:

If we were to move forward with you, which of your team members will be our main point of contact?
How available will you be outside of the scheduled meetings to address any of our concerns or additional requests?
What will be the frequency at which update meetings will be conducted, and who will be present at those meetings?
Which clinical study processes will be reported on, and what will be the workflow for how we will receive this information?
What will be the cadence at which we will receive progress reports?
Would we be able to access metrics electronically via an interactive dashboard, or will you send us formal reports?

Clara Health: At Clara Health, we directly interact and actively work with several key stakeholders involved in running a clinical trial, which includes sponsors, CROs, sites, and patients. This unique position allows us to have a centralized perspective which helps us to see all the moving parts of a clinical trial at the same time, which helps to identify issues and relay this vital information and insight back to the sponsor (or other appropriate stakeholders) in the shortest time possible.

The ability to access this perspective allows us to gather the most accurate, complete, and up-to-date information about how the clinical trial is unfolding, and quickly becomes very valuable to sponsors for their clinical trial.

As an example, we may receive feedback from patients about having an unsatisfactory experience with a particular study site. We are able to aggregate and analyze this information, and relay our findings back to the sponsor and the study site to improve the experience for other patients.

4. What Is The CRO’s Client Satisfaction Record?

It is a good practice to request information or metrics from the prospective CRO vendor that can point to the degree of satisfaction of their past clients. Prior to signing the contract, vendors will naturally do their best to uplift their image and future value to you during their sales conversations with you and your team. It can be tricky to get an objective understanding of what the partnership experience will actually entail, especially when there are multiple vendors fighting for your commitment.

We recommend that you ask the prospective vendor to provide success metrics regarding areas of clinical trial operations that are going to be important for your trial.

For example, you may be interested in learning about the vendor’s relationship to finances, in which case it will be useful to ask them about situations in which they went over the planned budget, and investigate into the reasons behind that. Alternatively you may be concerned about potential delays in timelines, in which case it would be helpful to learn about metrics regarding the CRO’s ability to meet timeline expectations.

You may also request to talk to the prospective CRO’s past clients, which will help you to gain insight into what the relationship was like and give you the opportunity to examine if the way in which the particular CRO manages its relationships and performs its services meets the expectations that you would have for your potential relationship and for your clinical trial.

Clara Health: At Clara Health, our relationships with our partners and with our patients are most important to us. In the unique position where we fit in the clinical trial process, we have the opportunity to directly co-create the clinical trial patient experience with a variety of stakeholders, including sponsors, sites, CROs, and patients.

Our company’s values and culture have been directed and developed to be such that the client and patient experience is at the top of priority for all of our internal teams, and we work to provide the best quality of care to all stakeholders.

We have many testimonials from every type of partner we’ve worked with which we can happily share with you.

5. How Do You Adapt When Encountering Challenges With Running A Clinical Trial?

It is inevitable that challenges and unforeseen changes will arise throughout the operational clinical trial process, and for this reason it is important to work with a CRO vendor that can provide you with evidence of their flexibility and ability to adapt to sudden changes.

The ideal CRO partner is one that is highly consultative throughout the entire process, and has an ability and the initiative to deal with challenges at their seed stage, prior to them turning into major obstacles for the success of your trial.

CROs naturally have a large reach, and there are a lot of different clinical trial mechanisms and processes that are under their control. They are able to monitor and respond to what is going on in every key link in the chain of the clinical trial operation.

It is reasonable to expect this level of oversight from a CRO, and additional questions that can help you gain insight into this include:

What are some examples where the CRO was effective at monitoring the health of clinical trials they’ve helped operate in the past?
How quickly does the CRO respond to challenges or opportunities for improving the clinical trial experience?
How well does the CRO gather & process information from study sites, study teams, patients & the sponsor, and what are their typical data analysis workflows?

It is also recommended to speak to the prospective CROs past clients to help you gain insight into how well they respond and adapt to the naturally arising challenges in clinical trials.

Clara Health: While CROs do have a large reach within the clinical trial, no CRO has complete visibility into every clinical process. They are not typically set up to support full visibility, which can manifest as a potential threat to your clinical trial as it unfolds. This is especially true for parts of the clinical trial processes that CROs naturally do not specialize and often subcontract, such as clinical trial recruitment.

At Clara, we are in a unique position in relation to other key partners involved in operating the clinical trial. We are in direct and frequent contact with patients, CROs, study sites, study teams, and the sponsor, and have a very deep understanding of the patient pipeline. This allows us the unique ability to go very deep into specific parts of the recruitment chain and investigate what is working and what is not working.

In addition, Clara functions as a resource for all partners in the clinical trial. For example, we work directly with site teams to ensure that they have access to a 3rd party that they can relay their needs to and receive fast support in case there is anything they require that can improve the patient recruitment process.

6. Which Parts Of Operating The Clinical Trial Will You Be Outsourcing?

Since there are so many processes and mechanisms that go into operating a clinical trial, CROs will always outsource some parts of running and managing the study. While you can expect that the prospective CRO will subcontract some of the work, it is important to find out which exact parts the clinical study will be outsourced.

There are certain basic and key clinical processes (such as site selection) that CROs almost always help with, and if you find that these parts of your trial are going to be subcontracted to another company, it is recommended to find out why the CROs operations are set up this way and how this would impact the service you will receive.

Ultimately what matters to you as a partner and client is that the quality of service and care that you will receive will be up to standard, and meet what was promised and what you are expecting. While this trust is important after you have signed the contract, it is recommended that prior to entering into such a significant commitment that you have evidence and the conviction that the CRO of your choice is truly the right fit and will deliver the quality of service that was being discussed.

Since it is impossible to predict exactly what the quality of this relationship and services performed will actually be like in practice, it is recommended that you understand the details of what will be done for your trial and how. Investigating how the CRO outsources and subcontracts services for a clinical trial will help you to gain necessary insight that you would need to make the correct vendor selection decision.

Clara Health: At Clara, we maximize the effectiveness of the digital component across the entire digital & recruitment spectrum, which is added on top of the existing capabilities of the CROs and other vendors involved in operating your clinical trial. In addition, we offer services that augment the CROs efforts, which has the potential to significantly improve the patient experience, operations flows, recruitment and retention performance, which is so important in ensuring the success of a clinical trial.

For example, if a CRO wants to have a great site relationship, we are able to come in as a third party on behalf of the sponsor and CRO and act as a resource and additional support for sites.

In another example, If a sponsor wants to have great relationships with the patient community, Clara is able to come in on behalf of the sponsor and develop these relationships while being perceived more neutrally by the patient community.

7. Do You Have Experience Running International Trials?

If you are planning on operating an international clinical trial, it is recommended to work with a CRO that has extensive experience in this area. While many CROs will offer near-global coverage, the level of experience with specific geographic locations can significantly vary from one vendor to another.

It is important to work with a CRO that has experience running clinical trials in the specific countries and regions you are planning to conduct your research in. Being compliant with the local rules and regulations for clinical testing is a very complex process that requires existing understanding and familiarity in order to ensure logistical smoothness and to mitigate legal risks. In operating a clinical trial, there are a multitude of clinical services and processes, which can greatly vary across the many regions in which you can conduct clinical testing.

A CRO that is lacking experience in operating international trials or operating in particular regions where you plan on conducting research may not be able to meet your desired quality and agility expectations, and therefore may not be the right fit for your international clinical trial.

Clara Health: In the past, we have provided international patient recruitment and digitally-augmented trial support services for clinical trials in the EU, Canada, UK, Australia and South America.

Clara Health is fully compliant to operate international studies everywhere in the world, with the exception of Russia and China.

8. What Is Your Relationship With Patients?

Patient-centric approach to designing and operating a clinical trial is becoming more and more crucial in the clinical research space. The ability of a sponsor and their CRO partner to understand the needs and characteristics of their target patient community is a significant determinant of whether or not the study will be a success.

A sponsor that has close and authentic relationships with the patient community tends to have a deeper understanding of how to create the best clinical trial experience that will attract patients and keep their interest throughout the clinical trial.

In addition, strong relationships with patients allow sponsors and CROs to forecast recruitment and patient retention pipeline with much higher accuracy. This ability is critical for ensuring the success of the trial and mitigating the risk of low enrollment. After an understanding of the patient population is acquired, sponsors gain the necessary insight to design a clinical trial that is not only favorable to their research results, but is also practical and will result in the enrollment numbers they are looking for.

While many CROs have already recognized the importance of patient-centricity and evolved the ways in which they design and operate clinical trials, other CROs have not yet made such a pivot in their values. It is important to understand the degree of importance the prospective CRO places on creating a favorable patient experience, and what kind of infrastructure the company has to support it.

At Clara, we recommend choosing a CRO partner that is adapting to the patient-centric model which is becoming more and more important for running a successful clinical trial.

Clara Health: Since early stages of our development, we’ve had a dedicated patient advocacy team that has been integral in shaping our company’s vision and operations. We have built our entire platform and recruitment infrastructure around creating the best experience for patients. Our teams, corporate values, service offerings and company infrastructure all work in the service of the patient.

In addition, over the many years of being in business we have heavily invested in building authentic patient community relationships that span across a variety of therapeutic areas. This has given us a unique ability to receive feedback directly from patients that is genuine and authentic around marketing materials, strategy for patient recruitment, and other services that we build for specific trials.

This ability to build partnerships with the patient community in an authentic way gives us a very unique ability to engage with the patient community on behalf of a pharmaceutical company, allowing our sponsor & CRO partners the opportunity to start conversations with patients through our in-house patient advocacy team.

If you would like to learn how Clara can help you to build a strong & authentic relationship with your target patient community, get in touch with us and we’d be happy to share our capabilities and previous results with you as they relate to your current or upcoming clinical trial.

9. How Is The CRO Going To Utilize Patient Input For Developing The Trial?

In the initial stages of clinical trial design, sponsors often determine the ideal patient profiles that would help them to drive the most favorable research outcomes for their study. While it is important for the success of your trial to determine who your ideal patients are, very often these projections do not match up with what is viable in practice.

At Clara, we often encounter study protocols that are not set up realistically for successful recruitment to be possible.

Common mistakes that are made when determining trial eligibility criteria and trial design include:

Overestimating the interest in the clinical trial from the target patient population
A lack of patient focus in the trial design
A lack of convenience for patients in their participation
Complicated and/or inefficient study experience flows
Crafting the eligibility criteria around the patient population that is most likely to lead to favorable study outcomes, without conducting sufficient research to more accurately estimate the recruitment and retention difficulty of the group for a particular study

It is natural for there to be a “push & pull” between the research ideal and the real world practicality. It is important to determine the correct balance between these two sides for your trial, as going too far in either direction will decrease the chance of your clinical study’s success.

The nature of the industry as it is right now is such that there is excess research idealization and not enough emphasis on patient centricity. This distorted orientation has resulted in many clinical trials being unsuccessful, negatively impacting sponsors, patients and the entire clinical trials industry.

The ideal CRO partner should help you make sure that your protocol design sets your study up for success. The CRO should be able to help you determine the proper balance between the research ideal and the real world practicality, and back up their findings with sufficient research and patient data that can project your trial being a success.

Clara Health: When formulating a recruitment and retention plan for our clients, we begin with conducting thorough research into the target trial patient population. This allows us to get a clear understanding of which recruitment channels will yield the best results and what kind of marketing materials will resonate with the prospective study participants.

To ensure accuracy and real-world applicability of our research, we consult and collaborate with our internal patient advocacy and patient support teams, as well as with our clients and patients representing the target trial patient profiles. We then tie our findings back with any existing proprietary data that we have in connection with the therapeutic area or the prospective target patient group.

Our unique position within the clinical recruitment chain gives us the presence and deep-rooted access needed to effectively tap into any of the three patient traffic sources: digital recruitment, offline recruitment, or patient advocacy recruitment.

Once a recruitment campaign has gone live, we constantly monitor, analyze and optimize our performance to make sure that the processes we have in place are as efficient as possible and drive the greatest results. In addition, we have the capability to layer in any traditional advertising (such as billboard ads) if requested by the study sponsor.

Top 10 Companies Sponsoring Clinical Trials

Learn about the top 10 companies sponsoring clinical research

Clinical trials are critical for advancing medical research and developing new treatments and therapies. These trials require substantial resources, and leading companies play a crucial role by sponsoring and supporting these endeavors. Several prominent companies have recognized the importance of clinical trials and have actively contributed to their success.

Pharmaceutical giants like Pfizer, Johnson & Johnson, and Novartis are among the leading companies sponsoring clinical trials. These companies invest significant financial resources and scientific expertise to bring new drugs and treatments to the market. By sponsoring clinical trials, they gain valuable insights into the efficacy and safety of their products, which helps them obtain regulatory approvals and ensure patient well-being. These companies often collaborate with academic institutions, healthcare organizations, and research centers to conduct large-scale trials and engage diverse patient populations.

Biotechnology companies such as Amgen, Gilead Sciences, and Moderna also play a vital role in sponsoring clinical trials. With a focus on innovative therapies and cutting-edge research, biotech companies contribute to advancing medical science. They often specialize in developing novel drugs and therapies, particularly in areas with unmet medical needs. By sponsoring clinical trials, these companies not only test the effectiveness of their experimental treatments but also support the scientific community in discovering new possibilities for disease management and prevention.

Medical device manufacturers like Medtronic, Abbott Laboratories, and Philips are another significant group of companies that sponsor clinical trials. They design and produce devices such as pacemakers, imaging systems, and surgical instruments. These companies sponsor clinical trials to evaluate the safety and efficacy of their devices in real-world settings. Through these trials, they gather data on device performance, patient outcomes, and usability, ensuring that their products meet the highest standards and address the needs of healthcare professionals and patients.

The importance of leading companies sponsoring clinical trials cannot be overstated. Their financial investments, research capabilities, and industry knowledge enable the successful completion of trials, leading to improved medical interventions and better patient care. Additionally, their involvement fosters collaborations between academia, healthcare providers, and industry, creating a rich ecosystem for scientific progress. By supporting clinical trials, these companies contribute to the growth of medical knowledge, the development of innovative treatments, and the overall improvement of global healthcare.

1. Pfizer: A Leader in Clinical Research

When it comes to clinical research, one name that stands out is Pfizer . They're making groundbreaking contributions through their involvement in clinical trials. Pfizer, a global pharmaceutical giant, has been at the forefront of clinical research for decades. They're driven by a passion for innovation and a commitment to improving lives through medical advancements. With their extensive resources and expertise, Pfizer has successfully conducted numerous notable clinical trials.

One remarkable example is the clinical trial that led to the development of the Pfizer-BioNTech COVID-19 vaccine . This breakthrough vaccine revolutionized the fight against the pandemic and offered hope to millions worldwide. It's a shining testament to Pfizer's dedication to tackling global health challenges head-on.

2. Johnson & Johnson: Advancing Healthcare through Trials

When it comes to advancing healthcare through clinical trials, Johnson & Johnson is dedicated to making a positive impact on people's lives by driving innovation through their commitment to clinical research. Johnson & Johnson is a renowned pharmaceutical and medical device company with a rich history of groundbreaking contributions to the world of healthcare. Their commitment to clinical research is unwavering, and they continuously strive to develop innovative solutions that address unmet medical needs.

One of the key areas where Johnson & Johnson has made a significant impact is in the field of oncology. Through their clinical trials, they have pioneered breakthrough treatments and therapies for various types of cancer . Their dedication to improving cancer care has offered hope and better outcomes for patients fighting this formidable disease.

In addition to oncology, Johnson & Johnson has been involved in numerous other clinical trials, exploring treatments for cardiovascular diseases, neurological conditions, and infectious diseases, to name just a few. Their diverse portfolio of trials showcases their wide-ranging expertise and commitment to advancing healthcare across various therapeutic areas.

3. Novartis: Pioneering Breakthroughs in Medicine

When it comes to pioneering breakthroughs in medicine, Novartis is at the forefront of clinical trials, driving innovation and transforming the lives of patients worldwide.

Novartis is a global healthcare company with a relentless commitment to improving patient outcomes through its involvement in clinical trials. They have made significant contributions to the development of innovative therapies and treatments across various therapeutic areas.

In the realm of oncology, Novartis has been a game-changer. They have conducted groundbreaking clinical trials that have revolutionized cancer care. Through their research, they have introduced targeted therapies and immunotherapies that are changing the way we fight cancer, offering new hope and improved survival rates for patients.

They have also made notable advancements in areas such as cardiovascular diseases, neurology, ophthalmology , and rare genetic disorders. Their commitment to diverse therapeutic areas demonstrates their dedication to addressing unmet medical needs and improving the lives of patients with various conditions.

4. Merck & Co.: A Legacy of Clinical Excellence

Merck & Co . has a long-standing commitment to advancing healthcare and has left an indelible mark on the world of clinical trials. Merck & Co. has been a driving force in the pharmaceutical industry for decades. Their involvement in clinical trials spans a wide range of therapeutic areas, from infectious diseases to cardiovascular health and beyond. With a legacy built on scientific rigor and a dedication to improving patient lives, Merck & Co. continues to make significant contributions to medical advancements.

One notable example of their groundbreaking research is the development of the human papillomavirus (HPV) vaccine . Through meticulous clinical trials, Merck & Co. brought this life-saving vaccine to the world, helping to prevent HPV-related cancers and protect countless lives. This achievement exemplifies their unwavering commitment to disease prevention and public health.

Merck & Co.'s commitment to clinical excellence and its transformative trials have made a lasting impact on global health.

5. Eli Lilly and Company: Transforming Lives through Research

Eli Lilly and Company 's dedication to clinical research is unwavering, and they have made significant contributions to the world of healthcare.

Are you curious about clinical trials?

One remarkable example of their impact is their work in the field of mental health. Eli Lilly and Company has conducted groundbreaking trials that have led to the development of medications for conditions such as depression , anxiety, and schizophrenia. Their research has provided hope to individuals and families affected by these challenging conditions.

Beyond mental health , Eli Lilly and Company has also made significant advancements in areas such as diabetes , oncology, and immunology. Through their clinical trials, they have introduced life-changing treatments that have the potential to save lives and improve the quality of life for countless patients.

6. Bristol-Myers Squibb: Advancing Cancer and Immunotherapy Research

When it comes to advancing cancer and immunotherapy research, Bristol-Myers Squibb (BMS) has a strong focus on these critical areas of healthcare and are committed to making significant strides in the fight against cancer.

Bristol-Myers Squibb has dedicated considerable resources and expertise to the field of oncology. They are driven by a passion to improve the lives of cancer patients and develop innovative treatments that target the disease at its core. Through its extensive research efforts, BMS has become a trailblazer in the fight against cancer.

BMS is also at the forefront of immunotherapy research, which harnesses the power of the immune system to combat cancer. Their trials focus on developing therapies that activate the body's own defense mechanisms to recognize and destroy cancer cells. This cutting-edge approach has revolutionized cancer treatment and provided new hope for patients.

When it comes to key clinical trials, BMS has numerous noteworthy examples such as the trial involving the development of a groundbreaking immunotherapy drug that targets specific proteins found on cancer cells. This therapy has shown remarkable efficacy in treating certain types of cancer, improving patient outcomes, and extending survival rates.

7. Sanofi: Innovating Healthcare through Clinical Trials

When it comes to innovating healthcare through clinical trials, Sanofi is committed to pushing the boundaries of medical research and developing life-changing treatments.

Sanofi has a deep-rooted commitment to clinical research and drug development. They believe in the power of scientific exploration to transform healthcare and improve patient outcomes. With its strong focus on research and innovation, Sanofi continues to make significant contributions to the medical world.

One area where Sanofi has made notable strides is in the field of rare diseases. Through their clinical trials, they have developed groundbreaking therapies that address the unmet medical needs of individuals with rare and complex conditions. These treatments have brought new hope and improved quality of life to patients who previously had limited options.

But Sanofi's impact extends beyond rare diseases. They have also conducted noteworthy clinical trials in areas such as cardiovascular health, diabetes, and immunology. Their dedication to diverse therapeutic areas demonstrates their commitment to improving healthcare across a wide spectrum of conditions.

8. AstraZeneca: Revolutionizing Medicine through Collaborative Trials

When it comes to revolutionizing medicine through collaborative trials, AstraZeneca is a standout. They believe in the power of partnerships and collaborative research to drive medical advancements.

AstraZeneca takes a unique approach to clinical research by fostering collaboration. They understand that by working together with scientists, healthcare professionals, and research institutions, they can accelerate the pace of medical breakthroughs. Through their collaborative trials, AstraZeneca aims to tackle complex diseases and develop innovative solutions that improve patient lives.

One area where AstraZeneca has made significant strides is in the field of respiratory medicine. Through their clinical trials, they have developed groundbreaking treatments for conditions such as asthma and chronic obstructive pulmonary disease (COPD). These treatments have provided relief and improved quality of life for millions of individuals affected by respiratory disorders.

AstraZeneca has also conducted notable clinical trials in areas such as cardiovascular health, oncology, and autoimmune diseases. Their commitment to diverse therapeutic areas demonstrates their dedication to addressing a wide range of medical needs.

9. AbbVie: Leading the Way in Biopharmaceutical Research

AbbVie is dedicated to pushing the boundaries of biopharmaceutical research and clinical trials scientific innovation and developing transformative treatments.

AbbVie has a strong focus on biopharmaceutical research, utilizing the power of biotechnology to develop cutting-edge therapies. Their commitment to scientific excellence is unwavering, and they continuously strive to address unmet medical needs and improve patient outcomes. Through their clinical trials, AbbVie is shaping the future of medicine.

One area where AbbVie has made significant strides is in the field of immunology. Their clinical trials have resulted in breakthrough treatments for autoimmune diseases such as rheumatoid arthritis and psoriasis . These therapies have provided much-needed relief and improved the quality of life for patients living with these chronic conditions.

AbbVie has also conducted notable clinical trials in areas such as oncology, neuroscience, and gastroenterology . Their diverse portfolio of trials demonstrates their commitment to tackling a wide range of medical challenges and improving healthcare across various therapeutic areas.

10. Gilead Sciences: Innovators in Infectious Disease and Beyond

When it comes to innovating in the field of infectious disease research and beyond, Gilead Sciences is a name that stands out. They are dedicated to tackling some of the most challenging health issues of our time.

Gilead Sciences has made significant contributions to infectious disease research, particularly in areas like HIV/AIDS and viral hepatitis. They have developed groundbreaking treatments that have revolutionized the lives of patients affected by these diseases. Gilead Sciences' relentless pursuit of scientific innovation has brought new hope to millions worldwide.

One key area where Gilead Sciences has made an impact is in the treatment of HIV/AIDS . Through their clinical trials, they have developed antiretroviral therapies that have transformed HIV/AIDS from a fatal disease to a manageable chronic condition. Their commitment to research and development has saved countless lives and improved the quality of life for individuals living with HIV/AIDS.

Gilead Sciences have also conducted key clinical trials in other therapeutic areas such as oncology, respiratory diseases, and liver diseases. Their diverse portfolio of trials showcases their dedication to addressing a wide range of health challenges.

The top 10 companies we've explored in this article play a pivotal role in advancing medical research and driving innovation in healthcare. From Pfizer to AstraZeneca, these companies are at the forefront of clinical trials, pushing the boundaries of scientific discovery and improving patient outcomes.

Their research has led to groundbreaking advancements in various therapeutic areas, from oncology to infectious diseases, immunology, and rare genetic disorders. Through their transformative trials, they have developed life-saving treatments, innovative therapies, and preventive interventions that have transformed the lives of countless individuals worldwide.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Explore content
About the journal
Publish with us
Sign up for alerts
Year in Review
Published: 07 December 2023

11 clinical trials that will shape medicine in 2024

Carrie Arnold 1 &
Paul Webster 2

Nature Medicine volume 29 , pages 2964–2968 ( 2023 ) Cite this article

101k Accesses

1 Citations

530 Altmetric

Metrics details

An Author Correction to this article was published on 04 January 2024

This article has been updated

Nature Medicine asks leading researchers to name their top clinical trial for 2024, from base editing and a vaccine against HIV to artificial intelligence tools for lung cancer and patient triage.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Rent or buy this article

Prices vary by article type

Prices may be subject to local taxes which are calculated during checkout

Change history

04 january 2024.

A Correction to this paper has been published: https://doi.org/10.1038/s41591-023-02781-y

Author information

Authors and affiliations.

Freelance writer, Richmond, VA, USA

Carrie Arnold

Freelance writer, Toronto, Ontario, Canada

Paul Webster

You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Arnold, C., Webster, P. 11 clinical trials that will shape medicine in 2024. Nat Med 29 , 2964–2968 (2023). https://doi.org/10.1038/s41591-023-02699-5

Download citation

Published : 07 December 2023

Issue Date : December 2023

DOI : https://doi.org/10.1038/s41591-023-02699-5

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Quick links

Explore articles by subject
Guide to authors
Editorial policies

22 Top Health Care Research Companies 2021

A Quirk's resource guide covering health care research firms

Applied Marketing Science (AMS)

Founded 1989 | 40 employees John Mitchell, President and Managing Principal

Phone +1-781-250-6300 ams-insights.com/insights-for-health care-markets

Ascribe Services

Founded 1999 Chrissy Stevens, Vice President, Services

Phone +1-877-241-9112 ext. 55 goascribe.com/products-services/ascribe-services

Decision Analyst Inc.

Founded 1978 | 150 employees Sara Sutton, Senior Vice President

Phone +1-817-640-6166 www.decisionanalyst.com/industry/medical

Founded 1980 | 250+ employees Steve Raebel, President

Phone +1-800-863-4353 www.fieldwork.com/medical-research-recruitment

Holden Healthcare

Founded 2006 | 50 employees Jeffrey Kelsch, Managing Partner

Phone +1-208-809-7117 E-mail [email protected] www.holdendata.com

Insights Opinion

Founded 2015 | 50 employees Sharoz Ghauri, CEO

Phone +1-646-475-7865 (U.S.) +91-120-498-7860 (India) www.insightsopinion.com

Ironwood Insights Group LLC

Founded 2017 | 300 employees David Bryant, VP Data Analytics

Phone +1-602-661-0807 ext. 2140 E-mail [email protected] www.ironwoodinsights.com

Just The Facts Inc.

Founded 1994 Bruce Tincknell, Managing Director

Phone +1-847-506-0033 www.justthefacts.com Testimonials www.justthefacts.com/testimonials-x-30

Kantar, Profiles Health Division

Founded 1996 | 600 employees in 25 countries Jennifer Carrea, Managing Director, Americas and Global Health, Kantar Profiles Division

hubs.ly/H0SLGCb0

Founded 2002 | 35 employees Paul Golota, CEO and Co-founder

Phone +1-866-963-3000 www.medsurvey.com

Mindspot Research

Founded 2006 | 8 employees Lynnette Leathers, CEO and Lead Moderator

Phone +1-407-730-4603 www.mindspotresearch.com

Murray Hill National

Founded 2013 | 35 employees Susan Owens, COO

Phone +1-972-707-7645 www.murrayhillnational.com

Olson Research Group Inc.

Founded 1995 | 45 employees Charles Olson, CEO

Phone +1-267-487-5500 www.olsonresearchgroup.com

Precision Research Inc.

Founded 1959 | 25-49 employees Scott Adleman, President

Phone +1-847-257-0827 RFQ [email protected] www.preres.com

Rare Patient Voice LLC

Founded 2013 | 14 full-time, 50 part-time patient advocates Wes Michael, President and Founder

Rare Patient Voice recruits hard-to-find patients and caregivers (rare and non-rare) in the U.S., Canada, U.K., France, Germany, Italy and Spain for qualitative and quantitative market research. We attend patient events such as conferences and walks to build our panels so that our patients are authentic and we can complete recruits within two weeks. We focus on recruiting only. With 100,000 patients and caregivers across 618 diseases/conditions, our panels include: all cancer types, Crohn’s, cystic fibrosis, diabetes, epilepsy, Fabry, Gaucher, hemophilia, HIV, Huntington’s, lupus, mental health, multiple sclerosis, Parkinson’s, primary immunodeficiency, PNH, pulmonary hypertension, sickle cell and spinal muscular atrophy. To get a bid with feasibility and costs at any time: pam.rarepatientvoice.com. Learn more about Rare Patient Voice and our services on our YouTube channel: www.youtube.com/watch?v=vq6n_JxtIDg&t=2s

Phone +1-410-218-0527 www.rarepatientvoice.com

RC Horowitz & Company Inc.

Founded 1983 | 5 employees Rob Horowitz, President

Phone +1-212-779-0033; +1-866-704-8000 www.rchorowitz.com

Reckner Healthcare

Founded 1991 | 225 employees Jason Gamber, Vice President

Phone +1-215-822-6220 recknerhealth care.com

Research America

Founded 1985 | 300 employees Robert Porter, CEO

Phone +1-610-356-1800 www.ResearchAmericaInc.com

Schlesinger Group

Founded 1966 | 1,200 employees Rob Ramirez, Chief Client Officer

Phone +1-203-899-0475 SchlesingerGroup.com

Shapiro+Raj

Founded 1955 | 80 employees Zain Raj, CEO

Phone +1-312-965-2319 www.shapiroraj.com

Founded 2000 | 1,400 employees Frédéric-Charles Petit, CEO

Phone +1-203-834-8585 www.tolunacorporate.com

WebMD/Medscape Market Research

Founded 1995 | 1,800 employees Audrey Rosen, Vice President, Market Research

Phone +1-212-624-3780 www.MedscapeMarketResearch.com

Survey Monitor March/April 2024 Related Categories: Health Care (Healthcare), Health Care (Healthcare) Research Health Care (Healthcare), Health Care (Healthcare) Research, Air Travelers, College Students, Education, Employees, Entrepreneurs/Small Business, Generation Baby Boomers, High-Tech, Higher Education, Research Industry, Shopper Insights, Travel

9 Top  Physician Research Companies Related Categories: Health Care (Healthcare), Health Care (Healthcare) Research, Health Care-Rare Patients Health Care (Healthcare), Health Care (Healthcare) Research, Health Care-Rare Patients, Physicians, Research Industry, Data Security, Medical, Nurses, Patients , Focus Group-Online, Journey Mapping

Navigating challenges of MedTech research with rare-disease patients Related Categories: Health Care (Healthcare), Health Care (Healthcare) Research, Health Care-Rare Patients Health Care (Healthcare), Health Care (Healthcare) Research, Health Care-Rare Patients, Research Industry, Medical, One-on-One (Depth) Interviews, Patients , Focus Group-Moderating, Qualitative Research, Recruiting-Qualitative

Have researchers become too good at finding  rare-disease patients to interview? Related Categories: Health Care (Healthcare), Health Care (Healthcare) Research, Health Care-Rare Patients Health Care (Healthcare), Health Care (Healthcare) Research, Health Care-Rare Patients, Research Industry, Medical, Patients , Respondent Cooperation/Satisfaction

Medical Research

Medical schools and teaching hospitals pioneer discoveries and innovations that save lives and transform health care.

Scientists and physicians at medical schools and teaching hospitals discover new treatments and bring them from the laboratory bench to the patient bedside. More than half of all research sponsored by the National Institutes of Health is conducted at medical schools and teaching hospitals. The advances and innovations that come from this research save lives and improve the quality of life for millions of patients.

As the leading voice and advocate for America’s medical schools and teaching hospitals, the AAMC champions an environment in which medical discovery can flourish, works to prepare a diverse medical research workforce, and strengthens the integrity of medical research.

A male and female researchers looking in microscope while working together on medical research in laboratory.

What's New in Medical Research

Podcast: a pivotal moment for science: a conversation with dr. francis collins .

In this episode of “Beyond the White Coat,” David Skorton, AAMC president and CEO, talks with Francis Collins, MD, PhD, director of the National Institutes of Health about how the United States can push ahead with the most critical research projects in a time when so much is constrained by unusual circumstances. The inaugural season of the "Beyond the White Coat" podcast features providers and researchers in academic medicine who discuss how they are responding to the COVID-19 pandemic. The podcast also examines ongoing, difficult conversations around clinical care and research. Learn more

Medical Research Initiatives

The AAMC leads and supports initiatives and projects to advance life-saving medical research that inspires members of the academic medicine community to serve the public, promote health, and improve care for all.

AAMC Center for Health Justice
Health System and Research Integration
Facilities and Administrative (F&A) Costs
Conflict of Interest and Transparency
Research Means Hope

Data & Reports

The AAMC publishes resources on topics related to medical research.

National MD-PhD Program Outcomes Study
MD-PhD Program Graduates: Current Workplaces, Research Effort, and Types of Research They Do
Assessing & Communicating the Value of Biomedical Research
Implementing the Regulations on Financial Conflicts of Interest: Results from the AAMC Conflict of Interest Metrics Project
Administration and Infrastructure for the Translational and Clinical Research Enterprise
The Functions of Centers and Institutes in Academic Biomedical Research

Medical Research Issues

The AAMC is a leading voice and advocate for the full spectrum of medical research. We work with federal policy makers to ensure that our members' perspective is incorporated into federal legislation and regulation.

Regulating Research
Basic Science
Research Training
Stem Cell Research
Research Evaluation
Clinical Research

Professional Development Resources

Attend an event.

Attend a meeting or webinar
Medical Research Webinars

Join a group

Join an affinity group or forum
Advisory Panel on Research
Council of Faculty and Academic Societies (CFAS)
Forum on Conflict of Interest in Academe (FOCI Academe)
Group on Educational Affairs (GEA)
Graduate Research, Education, and Training (GREAT) Group
Group for Research Advancement and Development (GRAND)
Research on Care Community (ROCC)

Mentoring Resources

Compact Between Biomedical Graduate Students and Their Research Advisors
Compact Between Postdoctoral Appointees and Their Mentors

Apply for an award or funding opportunity

AAMC Awards
Award for Distinguished Research
Robert Wood Johnson Foundation David E. Rogers Award

Learn Serve Lead

The AAMC’s annual meeting brings together diverse communities from across academic medicine so that professionals may learn from one another, find common ground, and build organizational capacity.

Affinity Groups

Professional development councils, groups, and organizations provide individuals at member institutions with access to leadership development, networking, and collaboration opportunities.

U.S. Department of Health & Human Services

Virtual Tour
Staff Directory
En Español

NIH partners with 11 leading biopharmaceutical companies to accelerate the development of new cancer immunotherapy strategies for more patients

Supports Cancer Moonshot goal to bring immunotherapy success to more patients in half the time.

Partnership for Accelerating Cancer Therapies word cloud

The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role.

“This new public-private partnership is a significant step forward in the battle against cancer and a real boost to the potential of immunotherapy,” said Acting Health and Human Services Secretary Eric Hargan. “We are excited for this partnership, which will strengthen efforts already underway across HHS.”

New immunotherapies have resulted in dramatic responses in certain cancer cases. They have also been the focus of intense investment by biopharmaceutical companies seeking to provide new options for patients who do not respond to other cancer therapies, but they don’t work for all patients. Development and standardization of biomarkers to understand how immunotherapies work in some patients, and predict their response to treatment, are urgently needed for these therapies to provide benefit to the maximum number of people.

“We have seen dramatic responses from immunotherapy, often eradicating cancer completely for some cancer patients,” said NIH Director Francis S. Collins, M.D., Ph.D. “We need to bring that kind of success — and hope — for more people and more types of cancers, and we need to do it quickly. A systematic approach like PACT will help us to achieve success faster.”

PACT will facilitate systematic and uniform clinical testing of biomarkers to advance our understanding of the mechanisms of response and resistance to cancer therapy. The research conducted under the partnership will also integrate immune and other related oncology biomarkers into clinical trials by defining a set of standardized biomarkers to be tested across a variety of studies. This approach will allow for consistent generation of data, uniform and harmonized assays to support data reproducibility, comparability of data across trials, and discovery and validation of new biomarkers for immunotherapy and related combinations. PACT will also facilitate information sharing by all stakeholders to better coordinate clinical efforts, align investigative approaches, reduce duplication and enable more high-quality trials to be conducted.

“A scientific and organizational challenge this complex cannot be addressed effectively by any one organization acting alone,” said Maria C. Freire, Ph.D., President and Executive Director of the FNIH. “Instead, it requires the energies and resources of public and private partners working in close collaboration.”

PACT partners include AbbVie, North Chicago, Illinois; Amgen, Thousand Oaks, California; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Bristol-Myers Squibb, New York; Celgene Corporation, Summit, New Jersey; Genentech, a member of the Roche Group, San Francisco; Gilead Sciences, Foster City, California; GlaxoSmithKline plc, Brentford, United Kingdom; Janssen Pharmaceutical Companies of Johnson & Johnson, New Jersey; Novartis, Basel, Switzerland; and Pfizer, Inc., New York. ( See what the partner organizations are saying about PACT ). Additional support has been provided by the Pharmaceutical Research and Manufacturers Association (PhRMA). The 11 partner organizations will contribute up to $1 million per year for five years through the FNIH for a total private sector contribution of $55 million. NIH will contribute $160 million over the five years of the partnership, pending availability of funds.

NIH’s National Cancer Institute (NCI) recently awarded cooperative agreements to support four Cancer Immune Monitoring and Analysis Centers (CIMACs) and a Cancer Immunologic Data Commons (CIDC) with a total of $53.6 million in funding over five years. The four CIMACs and one CIDC will form a network of laboratory centers that will support both adult and pediatric immunotherapy trials. Researchers at the CIMACs will perform deep tumor and immune profiling. The resulting data will be collected in the CIDC database for exploration of biomarkers of immune response. This network will also provide a foundation for the core laboratory, assay development and database functions required by PACT.

“NCI’s long-term support for basic and translational research in immunotherapy paved the way for the recent dramatic clinical successes in this area,” said Douglas R. Lowy, M.D., Acting Director of NCI. “This partnership, and the data the partners have committed to making publicly accessible to the broader research community, will facilitate our continued progress in helping to find the cancer treatments that benefit the greatest number of patients.”

The NCI cooperative agreements have been awarded to Dana-Farber Cancer Institute, Boston (CIMAC and CIDC); Stanford Cancer Institute, Stanford, California (CIMAC); Precision Immunology Institute and the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, New York (CIMAC) and University of Texas MD Anderson Cancer Center, Houston (CIMAC).

About the Foundation for the National Institutes of Health (FNIH): The FNIH creates and manages alliances with public and private institutions in support of the mission of the NIH. The FNIH works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit fnih.org .

About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI’s Contact Center (formerly known as the Cancer Information Service) at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov .

NIH…Turning Discovery Into Health ®

What PACT partners are saying

Multimedia: Partnership for Accelerating Cancer Therapies

Connect with Us

More Social Media from NIH

Drug development in this sector has high costs and low success rates, and there have been several expensive late-stage clinical failures. All these reasons have led to Big Pharma retreating from this sector over the last decade. This leaves disruptive startups to push forward innovation within neuroscience. Some of these startups are involved in researching treatments for neural diseases and mental health problems. According to Business Insider , startups in this field raised $548.5 million in investments between January 2022 and September 2022. From Capsida Biotherapeutics , which uses gene therapy to treat illnesses of the central nervous system, to Neumora , which combines data science and neuroscience to develop precision medications for brain disorders, startups are coming up with innovative solutions to neurological problems.

However, we must keep in mind that the majority of these treatments are still in the research stage and have not yet been approved for commercial usage. Recently, Eisai and Biogen announced that their drug, Lecanemab , slowed cognitive deterioration in Alzheimer's patients by 27% in a clinical trial. However, certain patients were also exposed to the drug's adverse side effects. This discovery caused quite a stir in scientific circles because it could be a significant breakthrough in Alzheimer's treatment if more studies and peer reviews establish its effectiveness and safety.

Photo by National Cancer Institute on Unsplash

On the other hand, some neuroscience companies have more futuristic ambitions. These startups promise to use technology to read your mind to treat illnesses and improve brain performance. Instead of creating drugs, the discipline of neuro-tech is concerned with the development of brain-machine interfaces, neuroprosthetics, neurostimulation, neuromonitoring, and other similar technologies.

Recently, Elon Musk's neuro-tech startup, called Neuralink , has gained a lot of public attention. The startup is developing a chip that would be implanted in a person's brain, where it would record the person's neural activity and potentially stimulate it. Synchron also proposes to enable direct brain control of mobility-assistive devices for paralyzed patients using implantable devices.

Other startups are developing wearable devices to monitor and regulate brain activity. Thync , for example, has created a small, wearable "pod" that attaches to the back of the neck and combats stress while also promoting better sleep. Another company, BrainCo , is working on brain-machine interface wearable headbands for mind-controlled gaming.

Startups like Nuralogix are promoting a more convenient approach to neurotechnology. Instead of specialist electronic gadgets, it has developed a smartphone application that uses AI to determine the user's health status. Its app, Anura, will collect a 30-second photo from your phone and produce a data archive covering various aspects of your health, such as heart rate and stress levels.

Our Methodology

Using stock screeners and manual research, we identified the biggest companies operating in the neuroscience space and ranked them in ascending order of their market cap. To accommodate major private companies, we took the average of five publicly traded neuroscience companies in our list to arrive at a revenue multiple of 6.5x, which we then used to estimate private companies' market cap and valuation. It is pertinent to note that our list comprises of both pure-play neuroscience companies and large biotech and pharmaceutical companies that have neuroscience divisions or related products.

Biggest Neuroscience Companies in the World

15. deepmind technologies.

Estimated Market Value: $9.19 billion

Annual Revenue 2021: £1.3 billion

Based in London, DeepMind Technologies is a leading artificial intelligence company combining aspects of systems neuroscience and machine learning to create powerful general-purpose learning algorithms. The company was founded in September 2010 and was acquired by Alphabet (NASDAQ:GOOG) in 2015. DeepMind Technologies has made significant contributions to the field of computer gaming, developing the AI program AlphaStar, which was able to beat professional players in the game StarCraft II. Moreover, the company has been able to develop a number of AI-powered tools and systems that have been used in the healthcare sector to improve patient outcomes and reduce costs.

14. Ipsen S.A. (EPA:IPN)

Market Cap as of January 07, 2023: $9.49 billion

Headquartered in Paris, France, Ipsen S.A. (EPA:IPN) is a biopharmaceutical company that develops and markets medical drugs focused on targeted areas like neuroscience, oncology, and rare diseases. Ipsen S.A. (EPA:IPN) is among the top pharmaceutical companies specializing in the field of oncology. The company also develops neurotoxins for disorders such as cervical dystonia, blepharospasm, cerebral palsy, and hemifacial spasm. The company's portfolio of products in the neurosciences area includes Dysport, a treatment for muscle spasticity, and Xermelo, a treatment for carcinoid syndrome.

13. Neurocrine Biosciences, Inc. (NASDAQ: NBIX )

Market Cap as of January 07, 2023: $11.38 billion

With a market cap of $11.38 billion, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is ranked 13 th on our list of the 15 biggest neuroscience companies in the world. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a research-based American biopharmaceutical company that operates in the research and development of therapies for neuroinflammatory, neuropsychiatric, and neurodegenerative illnesses and disorders. The company is working on treatments for conditions such as obesity, diabetes, Alzheimer's, insomnia, stroke, malignant brain tumors, multiple sclerosis, anxiety, and depression. The company's portfolio of approved products includes Ingrezza, a treatment for tardive dyskinesia, and Orilissa, a treatment for endometriosis.

12. Astellas Pharma Inc. (TYO:4503)

Market Cap as of January 07, 2023: $27.34 billion

Founded in 2005, Astellas Pharma Inc. (TYO:4503) is a Japanese multinational pharmaceutical company that engages in the research, development, production, and promotion of its products through its divisions in Europe, the United States., and Asia. The company’s operations are spread over multiple sectors, including oncology, urology, nephrology, immunology, neuroscience, and gene therapy. In the neuroscience segment, the company focuses on both central nervous system disorders and pain therapeutics. For central nervous system disorders, Astellas Pharma Inc. (TYO:4503) focuses on treatments for psychiatric disorders such as bipolar disorder and schizophrenia.

11. Biogen Inc. (NASDAQ: BIIB )

Market Cap as of January 07, 2023: $40.21 billion

Biogen Inc. (NASDAQ:BIIB) is an American multinational company that specializes in the research, development, production, and commercialization of therapies for patients globally. The company’s therapies are focused on oncological, neurological, and immunological disorders. The neurological disease areas Biogen Inc. (NASDAQ:BIIB) focuses on are amyotrophic lateral sclerosis (ALS), depression, lupus, multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s, and dementia.

10. Takeda Pharmaceutical Company Limited (NYSE: TAK )

Market Cap as of January 07, 2023: $49.53 billion

Headquartered in Tokyo, Japan, Takeda Pharmaceutical Company Limited (NYSE:TAK) is the biggest pharmaceutical company in Japan by revenue. The company is involved in the research and production of pharmaceutical products. The company's primary therapeutic areas of interest are oncology, gastrointestinal disorders, and diseases of the central nervous system. The disease areas Takeda Pharmaceutical Company Limited (NYSE:TAK) is working on are major depressive disorder (MDD), binge eating disorder (B.E.D.), and attention-deficit hyperactivity disorder (ADHD). The company also works on neurological conditions, including sleep-wake disorders, Parkinson’s disease, and rare epilepsies.

9. Amgen Inc. (NASDAQ: AMGN )

Market Cap as of January 07, 2023: $146.84 billion

Headquartered in California, United States, Amgen Inc. (NASDAQ:AMGN) is a multinational biopharmaceutical company and is the world’s largest pure-play medical biotechnology firm. Amgen Inc. (NASDAQ:AMGN) researches, develops, produces, and sells medications for severe diseases. The company focuses on developing innovative medications based on cellular and molecular biology with a particular emphasis on human treatments. In 2013, Amgen Inc. (NASDAQ:AMGN) acquired Onyx Pharmaceuticals to strengthen its portfolio of therapeutics oncology. In 2015, the company announced a collaboration with Novartis AG (NYSE:NVS) to work on the areas of migraine and Alzheimer’s. In 2021, Amgen Inc. (NASDAQ:AMGN) announced a collaboration with Neumora Therapeutics to advance their research on medicines for brain diseases.

8. Abbott Laboratories (NYSE: ABT )

Market Cap as of January 07, 2023 : $195.85 billion

Headquartered in Chicago, Illinois, United States, Abbott Laboratories (NYSE:ABT) is an American multinational healthcare and medical device company that researches, develops, manufactures, and commercializes a wide array of medical products and services. The product line of the company comprises nutritional, diagnostics, pharmaceuticals, and vascular products. The neuroscience products of the company focus on the treatment of diseases like epilepsy, headache, depression, sleep disorders, and migraine. Abbott Laboratories (NYSE:ABT) also offers neuromodulation therapies for patients with chronic pain or movement disorders by delivering stimulations directly to the dorsal root ganglion, spinal cord, and brain.

7. Novartis AG (NYSE: NVS )

Market Cap as of January 07, 2023: $199.60 billion

Founded in 1996, Novartis AG (NYSE:NVS) is a Swiss-American multinational pharmaceutical company that operates in the development and manufacturing of healthcare products. The company’s operations are divided into Sandoz International and innovative medicines. Its Innovative Medicine segment drives the majority of the company’s revenue through its global business franchises in oncology, immunology, neuroscience, ophthalmology, cardio-metabolic, respiratory, and established medicines. The neuroscience segment of the company is developing therapies for neurological disorders in three separate areas. In children, the research is focused on therapies for disorders such as spinal muscular atrophy (SMA), Rhett Syndrome, autism, epileptic encephalopathies, and intellectual disabilities. In adult psychiatry, the focused disorders are bipolar disorder, substance use disorders, depression, and schizophrenia, and in neurodegeneration, the company is working on Parkinson’s disease, several rare monogenic diseases, frontotemporal dementia, and multiple sclerosis.

6. AstraZeneca PLC (NASDAQ: AZN )

Market Cap as of January 07, 2023: $219.45 billion

AstraZeneca PLC (NASDAQ:AZN) is ranked 6 th on our list of the 15 biggest neuroscience companies in the world. Founded in 1999, AstraZeneca PLC (NASDAQ:AZN) is a multinational biotechnology and pharmaceutical company that commercializes drugs in several core therapeutic areas, including diabetes, cardiovascular, gastrointestinal, respiratory, cancer, immunology, and rare diseases. AstraZeneca PLC (NASDAQ:AZN), along with its partners across academia and industry, is working on therapies to treat disorders with unmet medical needs in the areas of chronic pain, cognitive disorders, and other disorders of the central nervous system.

Click to continue reading and 5 Biggest Neuroscience Companies in the World .

Integrated Clinical Trial Services to Advance Precision Medicine

Global trials for oncology, rare diseases and other complex diseases face unique challenges. precision partners with you to meet them head-on through our extensive footprint across the globe. we succeed by pairing personalized clinical services with translational medicine excellence, making us the first fully integrated clinical research organization created expressly to help advance the promises of precision medicine., the convenience of centralized services, with people across 70+ countries, our team provides comprehensive clinical trial services that streamline and accelerate drug development at a global scale, clinical trial management.

Fully integrated biomarker-driven trial management solutions—from study start-up through full-service execution—help accelerate your path to approval.

Clinical Development Strategy

Tailored strategies consider the scientific, regulatory, and commercial factors that shape each trial, mitigating risk and advancing the development pathway.

Clinical Trial Design

Advanced trial design approaches—including basket, umbrella, and adaptive trials—deliver biomarker-driven clinical research. Deep experience in these highly complex trial designs maximizes both insights and efficiency.

Biostatistics

Seasoned biostatisticians and statistical programmers deliver insight into every trial phase, from study design to regulatory submissions, all backed by meticulous documentation and data monitoring.

Clinical Sample Management

Sample inventories from a global network of labs supply real-time processing in 55 countries; consolidated data from central labs, screening labs, and specialty labs with clinical data create actionable reports.

Global Clinical Trial Support

Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

End-to-end, biomarker-driven clinical trial solutions

Full-service, complex, global clinical research organization services designed to accelerate the path to market.

Most Recent Posts

Case Study: AML Phase 1-2 Trial

Anne K. , Hasni M.

Navigating Cell and Gene Therapy Acquisitions: A Strategic Blueprint

Anshul M. , Tony K.

Why Select a Specialized Oncology CRO?

Frances M. , Teresa P.

Clinical data science: Trial management and operations empowered by data first

Better visibility, better collaboration, better execution. targeted solutions we’ve developed based on decades of experience and being at the forefront of modern drug development – focused on the opportunities to deliver the most value for your program.

Study design and tailored statistical analysis plans
Clinical Data Management delivered from more than 70 team members with an average of 12 years of data management experience
Clinical biometrics with a 100% EU regulatory agency data acceptance rate
Create submission-ready data sets (including CDISC) using a secure 21 CFR Part 11 and GDPR compliant infrastructure
Generate AI-derived signatures across integrated multiomic data and explore results in an intuitive, interpretable, and interactive interface
Know precisely where every sample is with our virtual sample inventory management (vSIM)

Our clinical trial services support preclinical to phase 4 studies around the world

Case study: exceeding enrollment expectations in a rescue study: a phase 3 registrational trial in multiple myeloma.

Precision was identified by a sponsor to rescue global and US management of a phase 3 registrational trial in relapsed, refractory multiple myeloma patients. This study targeted the enrollment of 780 patients at 155 sites in 20 countries.

The sponsor’s primary motivation for pursuing the shift to Precision from the other contract research organization (CRO) was based on their recognition that clinical research associates (CRAs) with little to no multiple myeloma experience and only minimal monitoring experience had been placed on their study. As a result of inefficiencies in operations, the study’s start-up was delayed.

Discover how our clinical trial services can advance your international clinical trial

Choose a contract research organization with precision.

A contract research organization (CRO) is crucial to medical research and development to provide support that includes clinical trial management and CRO research. The right outsourced CRO services can accelerate the overall process of drug development and market placement. Whether you need a CRO for clinical trials or a CRO for pharma, Precision has a solution that can be tailored to the needs of your study.

What sets Precision apart from other contract research organizations, is the way we integrate clinical trial execution with deep scientific knowledge, laboratory expertise, and advanced data sciences. This is Precision Convergence: maximizing insights into patient biology and accelerating the pace of scientific discovery and approval.

Explore Our Other Areas of Expertise

Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

1-888-664-9690

[email protected]

Corporate Brochure
Case Studies
Testimonials
Press Release
Vascular Surgeons Email List
Pathologists Email List
Gastroenterologist Email List
Chiropractors Email List
Anesthesiologists Email List
Plastic Surgeons Email List
Pediatricians Email List
Geriatricians Email List
General Surgeons Email List
Diabetes Specialist Email List
Allergist / Immunologist Email List
Arthritis Specialists Email List
Cardiologist Email Lists
Dermatologist Email List
Neurologists Email List
Orthopedic Surgeons Email List
Urologists Email List
Podiatrist Email List
Dermatopathologist Email List
Hematologists Email List
Pulmonologists Email List
Nephrologists Email List
Oncologist Email List
Rheumatologist Email List
Radiologist Email List
Optometrist Email List
Ophthalmologist Email List
Acupuncturist Email List
Optician Email List
Neonatologist Email List
Neuropathologist Email List
Hepatologist Email List
Traumatologist Email List
Gynecologists Email List
Psychiatrists Email List
Endocrinologist Email List
Hygienists Email List
Primary Care Physicians‎ Email List
General Practitioners Email List
Osteopathic Physicians Email List
Emergency Physicians Email List
Bariatric Physician Email List
Family Medicine Specialist Email List
Epidemiologist Email List
Clinical Lipidologist Email List
Registered Dieticians Email List
Psychologists Email List
Neurosurgeon Email List
Nutritionists Email List
Audiologist Email List
Hypnotists Email List
ENT Specialists Email List
Sleep Medicine Specialists Email List
Sports Medicine Physician Email List
Physiatrists Email List
Physician Assistants (PAs) Email List
Athletic Trainers (ATs) Email List
Cosmetologists Email List
Pediatric Allergists Email List
Naturopathic Doctors Email List
Veterinarian Email Lists
Phlebotomists Email List
Pediatric Radiologists Email List
AMA Physicians Email List
Paramedics and EMTs Email List
Pediatric Neurologist Email List
Preventive Medicine Specialist Email List
Reproductive Endocrinologist Email List
Interventional Cardiologists Email List
Nuclear Medicine Specialist Email List
Infectious Disease Specialist Email List
Radiation Oncologists Email List
Internal Medicine Specialist Email List
Mental Health Specialists/Professionals Email List
Addiction Medicine Specialist Email List
Aerospace Medicine Physicians Email List
Hematology & Oncology Specialist Email List
Medical Geneticist Email List
Addiction Psychiatrist Email List
Physical Medicine Rehabilitation Email List
Cardiac Care Nurses Email List
Critical Care Nurses Email List
Emergency Nurses Email List
Geriatric Nurses Email List
Home Healthcare Nurses Email List
Military Nurses Email List
Nurse Anesthetists Email List
Nurse Practitioners Email List
Registered Nurses Email List and Mailing List
Neurology Nurses Email List
Orthopedic Nurses Email List
Occupational Health Nurses Email List
Pediatric Nurse Practitioners Email List
Dermatology Nurses Email List
Perioperative Nurses Email List
Midwife Nurses Email List
Family Nurse Practitioners (FNP) Email List
Public Health Nurses (PHNs) Email List
Endocrinology Nurses Email List
Ambulatory Care Nurses Email List
Women’s Health Nurse Practitioners Email List
Adolescent Medicine Nurses Email List
Reproductive Health Nurses Email List
Transplant Nurses Email List
Dialysis Nurses Email List
Allergy / Immunology Nurses Email List
Family Planning Nurses Email List
ENT Nurse Practitioners Email List
HIV/AIDS Nurses Email List
Community Health Nurses Email List
School Nurses Email List
Student Nurses Email List
Nurse Manager Email List
Oncology Nurses Email List
Child Psychiatric Nurses Email List
IV Certification Nurses Email List
Licensed Practical Nurses Email List
Licensed Vocational Nurses Email List
Clinical Nurse Specialist Email List
Acute Care Nurse Practitioners Email List
Office Based Nurses Email List
Certified Registered Nurse Anesthetist Email List
Certified Nursing Assistants Email List
Psychiatric-Mental Health Nurse Practitioners Email List
Adult Care Nurse Practitioner Email List
Registered Pharmacist Email List
Hospital Druggist Email List
Druggist Email List
Community Pharmacists Email List
Pharmacist Clinicians (PhC) Email List
Ambulatory Care Pharmacists Email List
Pharmaceutical Email & Mailing List
Prosthodontists Email List
Periodontist Email List
Endodontists Email List
Pediatric Dentists Email List
Orthodontist Email List
Oral Pathologists Email List
Denturist Email List
ADA Dentists Email List
Dental Hygienist Specialists Email List
Oral and Maxillofacial Radiologists Email List
Oral and Maxillofacial Surgeons Email List
Subacute Care Centers Email List
Cancer Centers and Services Email List
Ambulatory Surgery Centers Email List
Diagnostic Imaging Centers Email List
Urgent Care Centers Email List
Trauma Centers Email List
Nursing Homes Email List
Nursing Home Administrators Email List
Hospital Email List
Assisted Living Facilities Email List
Medical Institutions Email List
X-Ray Laboratories Email List
Primary Care Centers Email List
Dental Clinics Email List
Blood Bank Centers Email List
Dental Laboratories Email List
Clinics Email List
Physical Fitness Facilities Email List
Med Spa Email List
Dental Equipment / Supplies Manufacturers Email List
Biomedical Equipment Manufacturers Email List
Electro-Medical Equipment Manufacturers Email List
X-Ray Apparatus and Tubes Manufacturers Email List
Ophthalmic Goods Manufacturers Email List
Surgical Appliances Manufacturers Email List
Surgical / Medical Instruments Manufacturers Email List
Neuromodulation Devices Manufacturers Email List
Cardiovascular Devices Manufacturers Email List
Therapeutic Devices Manufacturers Email List
Spine Devices Manufacturers Email List
Laboratory Equipment and Supplies Email List
Hospital Equipment and Supplies Email List

The Top 10 Clinical Research Companies in the USA

Dec 02, 2022
Posted By: admin

To bring effective medicines and Innovations in healthcare industry , a Clinical Research Organization or Contract Research Organization (CRO) are a must for the Biotech, Medtech, and pharma industries. A CRO offers comprehensive support to their efforts to test, examine, refine and market the latest medicines and devices that help in improving Healthcare Industry.

In 2022, the global clinical research market stands at $63.6 billion , and by 2027, it is expected to reach around an exciting amount of 115.1 billion with a CAGR of 11.0% from 2022 to 2027.

This growth is powered by an increase in R&D activities and expenditures and a significant rise in clinical trials owing to the need for innovations in healthcare. For that reason, it is also essential to be aware of the most prominent global research organizations that offer vital support with their specialized clinical trial solutions. This post will walk you through the ten big Clinical Research Companies In USA . So, let’s begin:

Founded: 1982
Headquarters: Durham, North Carolina
Annual Revenue : $13.87B
Employee Size: 88,000

IQVIA is one of the largest Clinical Research companies in the world that works profusely to enhance healthcare by integrating the study of human science with discoveries in technology and data science to improve understanding of human health and provide better and quicker care.

It helps pharma companies, along with other medical organizations, to innovate and maximize positive outcomes. In addition to clinical research and development, IQVIA has also developed analytics and technology solutions to aid the medical sector in commercializing products and enhancing customer engagement.

Some clinical trial solutions given by IQVIA are as follows:

Site identification & Selection
Help with protocol design
Design of clinical trial phase -1
Investigation and improvements of the clinical trial in phases 2 and 3
Accessibility to global laboratories

2. Pharmaceutical Product Development (PPD)

Founded: 1985
Headquarters: Wilmington, North Carolina
Annual Revenue: $65.0M
Employee Size: 24,000

PPD, also known as Pharmaceutical Product Development, is an extensive research organization headquartered in the United States but has a widespread global presence.

The company directs its attention to three prime areas: pharma development, lifecycle management services, and laboratory. Besides, it has clients and partners covering various sectors, including pharmaceutical companies, biotech firms, medical device manufacturers, and government or academic organizations.

Some clinical trials offered by PPD include:

Early Development
Consulting and Product Development
PPD Biotech
The site and patient-centered Solutions
Clinical Development

Headquarters: Waltham, Massachusetts
Annual Revenue: $3B
Employee Size: 18,000

Parexel is another important name in the list of Clinical Research Companies In USA that specializes on behalf of its pharmaceutical partners in carrying out clinical studies to boost and make certain that the medicine approval process takes place smoothly. It has a wide range of offerings that spreads across every type of clinical trial service to help sponsors work on creating successful trials.

Some of the clinical trial solutions which Paraxel offers:

Management of clinical data
Medical writing
Regulatory affairs consulting
Design and development of clinical trials at all phases
Clinical supply chain management

With pride, the company operates in over 50 countries and owns over 95% of the top 200 selling biopharmaceuticals in today’s market.

4. PRA Health Services

Founded: 1976
Headquarters: Raleigh, North Carolina
Annual Revenue: $64.3M
Employee Size: 16,400

PRA Health Sciences is a contract research organization that provides coverage in more than 90 countries worldwide. It principally centers on contributing therapeutic and operational expertise through integrated applications and supplying local expertise in particular areas. Besides, it works in the early and end stages of clinical trial procedures and the domains of strategy, consultancy, technology, and bio-analytics.

Moreover, it works hard to speed up medicine development operations to introduce better and more effective medicine sooner in the market.

Let’s take a peek at the PRA Health Sciences clinical trial solutions:

Onsite support services
Personalized solutions for Biotech
Clinical Diagnostics
Site Commercial Solutions
Protocol Consultation and Study Design
PRA’s Laboratories for Medicine Development

5. Syneos Heath

Founded: 1999
Headquarters: Morrisville, North Carolina
Annual Revenue: $5,213M
Employee Size: 28,000

With the merger of inVentiv Health and INC Research, Syneos Health was created that combines every discipline involved in bringing new therapies or products to market, from clinical research to consulting and commercialization.

Though it provides clinical development services spanning all stages, it primarily owns a specialization in helping healthcare organizations with the late stages of clinical trials. Moreover, its commercial solutions cover communication, consulting, and medication adherence.

The clinical trial solutions it offers include:

Early phase
Decentralized clinical trial solutions
Clinical data management
Pharmaceutical
Medical Device Diagnostics

Founded: 1978
Headquarters: Burlington, North Carolina
Annual Revenue: $16.1B
Employee Size: 70,000

Laboratory Corporation of America, or LabCorp, focuses on offering extensive clinical laboratory solutions and end-to-end medication and diagnostic development and commercialization.

The company develops special testing operations such as HIV genotyping, oncology testing, phenotyping, clinical trials, and diagnostic genetics. Moreover, its services are spread through care organizations, hospitals, government agencies, pharmaceutical companies, and physicians.

Some clinical trial solutions provided by LabCorp are:

Preclinical Services
Post-Marketing Solutions
Medical Devices
Clinical Trial Laboratory Services
Clinical Trials
Data & Technology

7. Charles River Lab

Founded: 1947
Headquarters: Wilmington, Massachusetts
Annual Revenue: $690.4M
Employee Size: 20,000

Charles River laboratories proudly span its capabilities throughout the medical R&D process from basic research to pre-clinical stage testing, manufacturing and commercialization within two significant services: Good Laboratory Practice (GLP) and non-GLP. It offers precise support to help its partners advance their research and efforts to introduce effective medicines in the market.

The company further serves biotechnology and pharmaceutical companies, hospitals, government agencies, and academic institutions.

Some of the clinical development solutions it offers include:

Bioanalysis
Clinical Kitting services
Data management
Quality control
Stability testing

8. Fisher Clinical Services

Founded: 1989
Headquarters: Center Valley, Philadelphia
Annual Revenue: $17B
Employee Size: 50,000

Fisher Clinical Services is a part of Thermo Fisher Scientific that has been for over 20 years in the business of supply chain management. It focuses exclusively on working with distribution and packaging requirements of clinical trials happening around the globe.

The company is committed to providing high-value products which adhere to the standard of pharmaceutical companies and is reliable, sustainable and perform well.

Some of the clinical trial solutions offered by Fisher Clinical Services are:

Cell & Gene Therapy
Clinical Label Services
Clinical Supply Optimization services
Direct to patient
Biologistics management

9. Medpace Holdings

Founded: 1992
Headquarters: Cincinnati, Ohio
Revenue: $1B
Employee Size: 1,001-5,000

Medpace offers support services for phases one to five of clinical trials for biotechnology, pharmaceutical companies, and medical device industries. It is a scientifically-driven organization that offers full service and helps industries make key differences with their contributions to the healthcare sector.

Some of the clinical research solutions that you receive from Medpace are:

Medical Writing
Quality Assurance
Clinical Monitoring
Clinical Trial Management
Risk-based Monitoring
Regulatory Affairs
Biostatistics and Data sciences

10. Advanced Clinical

Founded: 1994
Headquartered: Deerfield, Illinois
Annual Revenue: $106M
Employee Size: 501-1,000

A mid-size and full-service Clinical Research organization that helps sponsors run clinical trials and offers various solutions across therapeutic fields. It allows clients to secure better outcomes through candid discussions, conversations, foresight, and innovative solutions.

The company works hard to improve every life touched by clinical research. As such, some clinical solutions provided by Advanced Clinical are:

Project management
Clinical monitoring
eTMF and document management
Quality & Validation

The Bottom Line

There you have it – the best Clinical Research Companies In USA to get support from while working on new medicine or medical devices.

CROs play a critical role in the pharmaceutical, biotech, and medical device industries to manage and lead their clinical trials now more than ever due to rapidly rising prices, regulations, and tighter deadlines. Also pharmaceutical companies approaching Clinical Research Organizations for their R&D activities to stay competitive, flexible, and profitable against all odds.

IP Intelligence

R&d intelligence, life sciences intelligence, other services.

Visit the User Community

Patent Analytics

Eureka Materials

Data Service

Professional Services

Global Innovation Report

Success Stories

Help center

Al-Powered Innovation Intelligence

5 companies pioneering breakthrough cancer research .

In 2022, the global investment in cancer research reached a staggering $193 billion, reflecting the immense dedication and resources committed to unraveling the mysteries of this complex disease. And for good reason — every sixth death worldwide is attributed to cancer.

In this article, we’ll explore what cancer research is and highlight five companies pioneering the future of this devastating disease.

Jump to . . .

What is Cancer Research?
How Many Types of Cancer Exist?
What are the Current Treatments for Cancer?
5 Companies Pioneering Cancer Research
Bristol Myers Squibb
Curtis, Inc.

What is Cancer Research?

Cancer research is a multidisciplinary field dedicated to understanding the complexities of cancer, exploring its causes, mechanisms, and patterns, and developing innovative strategies to prevent, detect, diagnose, and treat this disease. It involves scientific investigations conducted by researchers, oncologists, biologists, geneticists, and other experts who collaborate to advance our knowledge of cancer at various levels, from cellular and molecular processes to clinical trials and population studies.

Cancer research encompasses a wide range of disciplines, including genetics, biochemistry, immunology, pharmacology, epidemiology, and computational biology. Through extensive laboratory experiments, clinical trials, data analysis, and translational research, scientists strive to unravel the fundamental mechanisms of cancer development, identify potential risk factors, discover new biomarkers, and develop novel therapies that can effectively target and eliminate cancer cells while minimizing harm to healthy tissues.

How Many Types of Cancer Exist?

The number of recognized types of cancer is not fixed and can evolve as our understanding of the disease advances. However, numerous known types of cancer are classified based on the organ or tissue in which they originate. Some common types of cancer include breast cancer, lung cancer, colorectal cancer, prostate cancer, skin cancer (such as melanoma), ovarian cancer, pancreatic cancer, and leukemia.

Additionally, there are less common and rare types of cancer that affect specific organs or tissues. The diversity of cancer types reflects the complexity of the disease and underscores the need for ongoing research and advancements in cancer detection, diagnosis, and treatment tailored to each specific type.

What are the Current Treatments for Cancer?

Current cancer treatments encompass a range of modalities aimed at combating the disease. These treatments include surgery, where tumors or cancerous tissues are physically removed through precise procedures. Radiation therapy utilizes high-energy beams to target and destroy cancer cells, while chemotherapy employs powerful medications to kill or control the growth of cancer cells throughout the body.

Immunotherapy boosts the body’s immune response to recognize and attack cancer cells, while targeted therapy utilizes drugs that specifically target molecules or pathways involved in tumor growth. Hormone therapy is employed for hormone-sensitive cancers, while precision medicine tailors treatment based on an individual’s genetic profile and specific biomarkers.

These treatment approaches are often used in combination, with personalized treatment plans designed in collaboration between patients and a multidisciplinary healthcare team.

5 Companies Pioneering Cancer Research

1.) genentech (roche) : .

Genentech, a leading biotechnology company, is spearheading cancer research with its groundbreaking advancements in personalized medicine and targeted therapies.

Through extensive genomic analysis and precision medicine approaches, Genentech focuses on developing therapies tailored to specific cancer types and individual patients. Genentech’s commitment to understanding the molecular basis of cancer enables the development of effective treatments that can directly target cancer cells while minimizing damage to healthy tissues.

Through analysis on Patsnap’s platform , Genentech is focusing on Antiendomysial antibodies in 2023. Last year the company’s primary research objective revolved around mitigating the severity of the disease.

2.) Novartis

Novartis, a global pharmaceutical company, is revolutionizing cancer treatment through innovative therapies, including targeted therapies, immunotherapies, and cellular therapies.

Novartis has made significant strides in the field of CAR-T cell therapy, a groundbreaking approach that harnesses the power of a patient’s immune system to recognize and destroy cancer cells. Novartis’ commitment to pushing the boundaries of science and collaboration has led to remarkable advancements in cancer research and treatment options.

Over the last three years, the company has been focused on improving security, stability, and other effects. Novartis AG is also increasing its focus on solving problems that increase the risk of its pharmaceuticals.

3.) Bristol Myers Squibb

Bristol Myers Squibb (BMS) is a renowned pharmaceutical company known for its pioneering research in oncology. BMS focuses on developing innovative immunotherapies that activate the immune system to fight cancer.

The company’s checkpoint inhibitors, which target proteins that suppress the immune response, have transformed the treatment landscape for various types of cancer. BMS continues to explore new therapeutic avenues, aiming to enhance patient outcomes and improve survival rates.

In 2022, BMS directed significant IP attention towards multiple areas, including reducing tumor quantity, tumor shrinkage, stabilizing disease progression, achieving durable clinical responses, and attaining complete responses.

4.) Moderna

Moderna, a pioneering biotechnology company, has made disruptive contributions to cancer research through its mRNA technology platform.

While mRNA vaccines have gained prominence in recent times, Moderna has also been harnessing this technology for cancer immunotherapy. Moderna’s personalized cancer vaccines, which leverage the body’s immune response to target tumor-specific antigens, hold great potential in treating a wide range of cancers. Moderna’s innovative mRNA-based therapies are reshaping the landscape of cancer treatment.

This year, Moderna is intensifying its R&D efforts in the fields of polynucleotides, nucleotides, and fusion proteins, with a keen awareness of their potential implications for specific health concerns. Additionally, the company is actively dedicated to facilitating broader accessibility to RNA therapeutics, aiming to simplify its acquisition process and ultimately extend its benefits to a larger population.

Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company has identified several promising drug candidates that have shown significant efficacy in preclinical and clinical trials.

Its portfolio includes small molecule inhibitors and monoclonal antibodies designed to selectively target and inhibit the activity of proteins involved in cancer cell proliferation and survival. The company has also demonstrated a commitment to precision medicine by incorporating genomic profiling and biomarker analysis into its clinical trials. By identifying specific genetic alterations and biomarkers associated with treatment response, Curis aims to personalize treatment decisions and maximize the chances of success for individual patients.

“With Patsnap email alerts, I can get weekly updates on competitor patent filings and specific technology spaces sent straight to my inbox. This has saved us a lot of valuable time which would have otherwise been spent searching and sorting through patent documents. Overall, PatSnap makes our innovation process much more efficient.” -Mark Noel, Vice President of Technology and IP, Curis Inc.

In the quest to conquer cancer, these five companies are disrupting cancer research. Driven by a relentless pursuit of breakthroughs, they are reshaping our understanding of cancer, redefining diagnostics, and reimagining treatments.

Analytics Eureka Discovery Synapse Bio Chemical
Community Customer Stories Global Innovation Report Webinars Newsletter About us
Book a demo

Subscribe or renew today

Every print subscription comes with full digital access

Science News

How patient-led research could speed up medical innovation.

People with understudied chronic conditions are taking up science

Digital art of someone in a hospital gown standing at a line graph full of data points with other images such as lungs, chemical makeup and bell curves around the person.

Suffers of long COVID, ME/CFS and other chronic conditions are taking medical research into their own hands.

Experimental design

Remission Biome is studying whether changes to the gut microbiome can improve the health of people with ME/CFS or long COVID. Participants follow a protocol that includes taking prebiotic and probiotic supplements and a course of antibiotics.

Initial safety checks and testing : Samples from several body systems are collected and analyzed to ensure it’s safe for a volunteer to participate and to collect baseline data.

Symptom tracking : Participants record their symptoms throughout the project.

Start supplements : Participants begin taking prebiotics and probiotics.

Antibiotic added : An antibiotic is added to the regimen for 14 days.

Post-antibiotic testing : Body systems are checked again to look for changes.

Result : Remission Biome members hope to experience some symptom relief, as well as publish study findings and inspire new research projects for professional scientists.

A history of patient activism and patient-led research

About 1.3 percent of adults in the United States have ME/CFS, according to the U.S. Centers for Disease Control and Prevention. Scientists first noticed the condition in the 1930s, but since then, it’s been hard to define and hasn’t attracted extensive research attention. Initial observations noted outbreaks characterized by fatigue, chronic pain and other symptoms now associated with ME/CFS, often occurring — but not always — after viral infections. Scientists started to link these mysterious outbreaks in the 1980s under the umbrella term chronic fatigue syndrome.

Progress on identifying the disease’s triggers has been slow, in part because of the wide variety of symptoms across many organ systems and in part due to relatively limited research funding. And some doctors have dismissed patients’ symptoms as all psychological — a factor that some experts connect to the disease’s higher burden on women.

Combined, these challenges have contributed to a lack of treatments for people with ME/CFS, despite the illness’s potentially devastating impact on patients. Long COVID — which 6.8 percent of U.S. adults currently have, according to data from the CDC and U.S. Census Bureau — raised the profile of ME/CFS during the pandemic because of the two conditions’ similarities ( SN: 3/4/24 ).

“Biomedical research has blind spots.” Susannah Fox

Remission Biome started thanks to a Twitter conversation in fall 2022. Falor and Romanuk realized they had both independently experienced what they call “remission events,” in which symptoms recede for a few hours or days after courses of antibiotics. These events led each of them to look into the possible connection between ME/CFS symptoms and the gut microbiome, an emerging area of study with many unanswered questions. The pair were also both working scientists before their symptoms became debilitating. Falor had worked as an aerospace engineer at NASA; Romanuk had been a biologist studying microbiomes.

The two scientists set out to replicate their remission events — and collect extensive data on how their microbiomes and bodily systems changed to better understand the underlying biology of these events. They started with a self-test in early 2023, which included taking a lengthy list of supplements chosen to either increase or decrease levels of specific bacteria with possible ME/CFS connections. In addition to Romanuk and Falor, Isabel Ramirez-Burnett, a 50-year-old engineer and health coach in Rhode Island who has lived with ME/CFS since childhood, participated in the experiment.

The testing “went even better than we could have expected,” Falor says, with two of the three participants experiencing remission events. So Remission Biome expanded to the Renegade 50 cohort and fundraised through a crowdfunding campaign, grants and sponsorships to support this larger project. The team also recruited the participants’ physicians, to help ensure safety, along with scientists to collaborate with the participants and other volunteer researchers working on the project. Scientists regularly attend research meetings hosted by Remission Biome, Falor says, which include presentations and discussions about new, relevant findings in other ME/CFS and long COVID research.

Theoharis Theoharides is one of those scientists. As director of the Center of Excellence for Neuroinflammation Research at Nova Southeastern University in Clearwater, Fla., he has decades of experience studying mast cell activation syndrome, a chronic condition characterized by intense allergic reactions that is often diagnosed alongside ME/CFS and long COVID. “They’re very bright, very dedicated,” Theoharides says of Falor and Romanuk. He has provided feedback on Remission Biome’s regimen of supplements and plans to help analyze microbiome and blood samples taken from the Renegade 50 participants to look at how immune system changes may connect to their gut bacteria.

Another collaborator is Tatyana Dobreva, cofounder and CEO of the San Francisco–based biotech start-up ImYoo , which operates remote clinical trials and other research. ImYoo is assisting Remission Biome with genetic analysis of patient blood samples. The Renegade 50 study is similar to other ImYoo projects studying conditions such as inflammatory bowel disease and sickle cell disease, in which participants tie symptom tracking to data from medical testing, Dobreva says.

Remission Biome adds to a long history of patients with complex and contested illnesses advocating for their communities, Fox says. “Every decade of the 20th century had an example of people who were either being ignored or who were being discriminated against” by scientists and doctors, and who “banded together to innovate or gather data,” she says. Examples include Black people with sickle cell disease in the 1970s and people with HIV/AIDS in the 1980s ( SN: 12/8/23 ). In some cases, this translated to patient-informed research, in which patients consult on scientific projects, informing everything from research questions to how results are disseminated.

A vintage photograph of a Sickle Cell Anemia Testing site hosted by the Black Panther Party. Children are getting tested while standing close to their parents. There's a banner behind the testers that reads: "SICKLE CELL ANEMIA TESTING Black community survival conference"

In the 21st century, the internet aided patient-led projects, with patients actually doing research, as like-minded patients could more easily find each other, as happened with Romanuk and Falor, Fox says. In these projects, patients also closely follow scientific studies about their disease and may collaborate with academic experts to develop scientific frameworks, rather than self-experimenting individually.

ME/CFS patients have been particularly motivated to pursue their own research, says Emily Taylor, vice president of advocacy and engagement at the ME/CFS organization Solve M.E . One key motivator is “the failure of the medical establishment to provide any sort of support or treatment or quality of life improvements for this population,” she says. Previous ME/CFS research done without patient input, such as a now-debunked clinical trial examining exercise as a potential treatment, has led patients to push back with their own studies.

“There was a desperate need to validate the anecdotal stories of patients in a formalized way,” Taylor says.

In spring 2020, during the first months of the pandemic, patients whose symptoms persisted for weeks after the initial infection started documenting their complex symptoms in real time. The Patient-Led Research Collaborative , or PLRC, formed out of a long COVID support group, led by members who had scientific experience.

PLRC released its first report in May 2020 , documenting symptoms common among the group’s hundreds of members. “We saw a need to start collecting people’s experiences and really try to take things into our own hands,” says PLRC cofounder and long COVID patient Lisa McCorkell.

U.S. adults who have ME/CFS

U.S. adults who have long COVID

Patients are experts

Patient-led and patient-informed research can be a win-win for both patients and scientists, advocates say. For patients, this work is more likely to address questions that are meaningful to their daily lives, says Jaime Seltzer, director of science and medical outreach at the advocacy group #MEAction . In one pre-pandemic example, a patient group focused on polycystic kidney disease proposed potential treatments to scientists at the University of Cambridge, leading to clinical trials at a new patient-led research hub.

Patient leadership can also inspire people to participate in clinical trials, as the interest in joining Remission Biome demonstrates. And study designs informed by patient experience often prioritize accommodations for people with different levels of symptoms or access to care, meaning a more diverse group of patients may be able to participate. With a patient-led, “decentralized” approach to research, “we can reach more people in more diverse areas” who don’t live near medical facilities in big cities or aren’t able to travel for clinical trials, Dobreva says.

Connor, a member of the Renegade 50 who asked that only his first name be used to maintain medical privacy, “couldn’t participate in a traditional study,” says his wife, Nicole Bruno. Since a COVID-19 infection two and a half years ago, he has faced a severe case of both long COVID and ME/CFS, leaving him bedbound in a dark room.

“He could never go to a lab” or a doctor’s office to have samples collected, Bruno says. But with Remission Biome’s remote framework and individual support, he can be a patient-researcher. In addition to flexibility in locations, each member of the cohort is going through the testing protocol at their own pace, incorporating their microbiome test results, other diagnoses and input from their physicians. Flexibility also helps with logistical challenges; for example, test kits take longer to ship internationally.

For scientists, patient-led studies may move a field forward by highlighting key questions and hypotheses that might not emerge from traditional research. “Biomedical research has blind spots,” Fox says. McCorkell points to a paper from the PLRC , published in eClinicalMedicine in 2021, that expanded upon its 2020 survey work by describing 200 long COVID symptoms across 10 organ systems based on a detailed survey of about 3,800 people.

“It is still, to this day, one of the most cited papers in long COVID,” McCorkell says. Without this paper, she adds, other scientists might still be investigating “a small, limited set of symptoms” rather than the full scope of the condition. David Putrino, a long COVID clinician and director of rehabilitation innovation at Mount Sinai Health System in New York City, also points to the PLRC paper as an example of successful patient-led research that informed later studies.

Patient-led research “moves orders of magnitude faster than traditional modes of research,” Putrino says, because it focuses on the questions that are of greatest concern to patients, leading more quickly to impactful results. Patient-led groups may also be able to start new studies more quickly than institutions that have to, say, go through formal academic procedures, he says. In that way, this research is similar to how start-ups move faster than large corporations.

In addition, patients can help scientists design studies that are more likely to provide accurate results. For example, feedback from members of Remission Biome and other patient representatives helped David Esteban, a biologist at Vassar College in Poughkeepsie, N.Y., who was looking for people who had gotten COVID-19 but didn’t develop long COVID and could serve as control patients in a project funded by PLRC.

“Their perspective was, many people who recover from acute COVID go through a period where they feel better, but then get worse again,” he says. “I hadn’t really thought about that.” But that insight helped Esteban establish how long after a COVID-19 infection to wait before declaring a patient past the threshold for developing long COVID.

After studies are completed, patient teams may be more thoughtful about communicating results back to patient communities. In sharing a recent paper about managing ME/CFS that she coauthored with clinicians at the Mayo Clinic in Rochester, Minn., for instance, Seltzer anticipated questions that ME/CFS patients might have about the study. She explained up front that the paper was a concise review and could not include every relevant study, as patients would want to know “why I hadn’t mentioned their favorite paper,” she says. Such communication can “save a research group a lot of time and energy,” Seltzer says, and can encourage patients to bring the paper to their doctors so that the findings might inform their health care.

Groups like PLRC are working to build infrastructure to help scientists better engage with patients, including experienced patient-researchers and others who haven’t done scientific work before.

In January 2023, PLRC and the Council of Medical Specialty Societies introduced scorecards for academic teams interested in these collaborations. The scorecards can help teams evaluate success. “Our scorecards were developed with the intention of trying to change the baseline of what’s considered acceptable patient engagement,” McCorkell says, moving away from “tokenizing” engagement that she and other PLRC members have experienced. Taylor, at Solve M.E., would like to see the scorecards or a similar evaluation incorporated into traditional funding applications at scientific institutions.

ME/CFS funding

Of 73 diseases (dots) with research funding from the National Institutes of Health, ME/CFS is among those underfunded relative to its disease burden, the total number of healthy years lost due to premature death or disability from illness. The graph includes an estimate of ME/CFS burden with the arrival of COVID-19. The red line is expected funding levels based on burden.

NIH funding vs. disease burden, 2020

Scatterplot of NIH funding (in millions of dollars) vs. disease burden (in millions of lost years) for 2020.

The challenges of patient-led research

Current institutional and financial support for patient-led research projects is limited. These projects typically are not eligible to apply for academic and government grants, leading them to seek money from nontraditional sources. Patient-researchers also don’t tend to have access to laboratory space, clinical tests and other research resources.

“We’re limited in the type of research that we can do,” McCorkell says. As a result, surveys and self-experimentation are the most common methods.

Internal capacity is another challenge: Chronically ill people tend to have limited energy to devote to projects; they must balance this work with managing their symptoms. Patients tend to be more ambitious than their available energy can support, Seltzer says. Sometimes a patient-researcher might have to take a break from a project to recover from a symptom flare-up. Projects like Remission Biome take these crashes into account when designing experiments and distributing tasks.

“If I disappear for a week,” it’s OK, says Katrin Boniface, a doctoral student studying the history of horses at the University of California, Riverside who had her own remission experience before joining the Renegade 50. But these constraints might frustrate academic or clinician collaborators who want patient-researchers to answer emails at all hours or pull together a last-minute grant proposal.

Nonpatient scientists might also be skeptical of results from patient-led research, as many in the scientific community haven’t yet recognized how lived experience can improve studies, Seltzer says. Although many patient-researchers have scientific backgrounds, they might not be experienced in biomedical research, leading to perceptions that they are underqualified and that their work is not rigorous or may even be biased.

Advocates like Seltzer argue that patient-researchers are more incentivized than anyone to make sure their results are accurate. “If we’re wrong, we and people like us suffer,” she says.

Taylor argues that data from patient-led research should be added to the types of evidence that regulatory agencies like the U.S. Food and Drug Administration consider for approving treatments. The FDA and the National Institutes of Health took one step in this direction earlier this year by soliciting data from long COVID patients and doctors about their experiences with treatments approved for other diseases.

“There was a desperate need to validate the anecdotal stories of patients in a formalized way.” Emily Taylor

But some scientists and doctors are concerned that patient-led projects might encourage some patients to self-experiment on their own without appropriate safety measures. This has been a big challenge for Remission Biome, especially after its members posted about remission events during the project’s first phase in early 2023. Initially, the plan was to openly share all aspects of the project, including protocols and results, says Ramirez-Burnett, one of the three early participants. “But then we realized that people were starting to pick pieces of the protocol in order to do it, which is not safe,” she says. “So we had to close that document.”

Now, when asked about the full protocol, as they often are on social media, Remission Biome participants typically encourage safety and emphasize that more testing is needed before it’s widely shared. In the future, Ramirez-Burnett hopes to educate more clinicians about the project so they can work with patients outside the Remission Biome infrastructure.

Patient-led projects may also struggle with logistics. This has been the case for Remission Biome. Its two founders split in December over disagreements about the project’s pace, its handling of safety aspects and how to incorporate the project as a formal business. As a result, Romanuk and the group parted ways.

The Renegade 50 test was put on hold until mid-March while Falor and other project members addressed this leadership change and set up as a nonprofit, she says. The team is also adding more safety steps and participant education on the antibiotic in the testing protocol because that antibiotic may have negative side effects for some people with ME/CFS. Falor expects the Renegade 50 phase will be completed later this year, after which the project will share preliminary results and begin setting up a cohort of 500 participants.

Tests and supplements for that next cohort will require more financial support, which Remission Biome will continue to raise from its GoFundMe campaign and grants. The project has also secured sponsorships from supplement and testing companies, such as the probiotics provider FitBiomics, to provide research supplies to participants. Financial support is especially important for participants living in places where it’s difficult to receive medical care for ME/CFS, says Richardson, the Renegade 50 member in Mexico. Many patients globally could benefit from this work, she says.

Remission Biome is also working toward scientific publications, based on data from the Renegade 50 cohort and from side projects. But the 50-person test might not lead to publishable results, says scientist-collaborator Theoharides. The microbiome is extremely complex, and, unlike a clinical trial, the Renegade 50 group does not include control patients not taking the treatments. But he hopes “the information that will come out of this study might actually give us some new directions.” One key advantage, he says, is that each participant is testing many supplements rather than focusing on one at a time; ME/CFS and long COVID are such complex diseases that it’s unlikely for a single treatment to work for all patients or have a lasting impact.

Esteban, the biologist at Vassar College, similarly hopes to examine how different antibiotics might work together to alleviate symptoms. “I’m already thinking about experiments that I could do,” he says, such as work in lab animals that would “start to explore some of the proposed mechanisms that might underlie the effects they’re seeing with the antibiotic treatments.”

While Remission Biome’s participants are excited to contribute to research, their most important goal is to provide “solutions for the ME/CFS community,” Ramirez-Burnett says. “So people don’t have to lose their jobs, lose their relationships, not get proper care.”

Among the three Renegade 50 participants who had completed the testing protocol as of January, one experienced a remission event, signifying a potential success, Falor says. Meanwhile, the project’s frequent meetings, Slack group, apps for shared symptom-tracking and other communication options could provide models for other patient-research efforts.

Remission Biome participants who have dealt with ME/CFS for a long time, like Richardson, feel particularly motivated to help find answers for the millions around the world newly struggling with long COVID. “People with mild long COVID sound like what I experienced 20 years ago,” Richardson says. She hopes that the lessons learned from Remission Biome and other projects like it can help prevent new long COVID patients from experiencing decades of symptoms.

Here’s what distorted faces can look like to people with prosopometamorphopsia

Close-up of a young woman's sweat-stained underarm area.

These are the chemicals that give teens pungent body odor

A foggy image of a woman with long, dark hair swept to the left.

Brain fog is a debilitating symptom commonly reported by people with long COVID. Now, scientists have linked the symptom to leaky boundaries in the brain.

Long COVID brain fog may be due to damaged blood vessels in the brain

A single silver tap protrudes from a crumbling beige tiled wall. There is a stream of water running from the tap. A circular inset with a triangle pointing to the water has an illustration of one pink blobby amoeba with at least five knobby protrusions. Part of another pink amoeba is visible in the left side of the circle.

Don’t use unsterilized tap water to rinse your sinuses. It may carry brain-eating amoebas

Bundled in layers of warm clothing, a pedestrian in Minneapolis braves a freezing day

The U.S. now has a drug for severe frostbite. How does it work?

A sea of white flags planted in the ground wave in front of the Washington Memorial. Each flag represented a person in the United States who had died from COVID-19 by early fall 2021.

Four years on, the COVID-19 pandemic has a long tail of grief

Illustration of a woman balancing on green columns that appear to be wobbling. Blown-up icons of coronavirus fill the spaces between the columns.

The blood holds clues to understanding long COVID

Paper that reads "Diagnostic assessment" and "Diagnosis: Urinary Tract Infection" appears next to a syringe and a pill canister.

Here’s why pain might last after persistent urinary tract infections

From the nature index.

Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.

Not a subscriber? Become one now .

My Top 3 Companies Paving The Way For Medicinal Cannabis Research

Recent rush into the cannabis sector and growing interest in researching the medicinal potential of cannabis and its diverse array of cannabinoids.
Seemingly endless viable (from an early standpoint) treatment options through the endocannabinoid system.
GWPH and ABBV already have cannabis-related drug products that are FDA-approved, with CARA chasing approval as well.

The green rush is nothing new to investors that have been following developments over the last few years. As legalization across the nation continues to grow and with mounting pressure on the federal government to move towards legalization, stigma towards cannabis is diminishing at an increasing rate. We continually hear about companies such as MedMen, Halo Labs, and other dispensaries, brands, and distributors. However, we hardly think of the scientists and companies paving the way for medicinal uses of cannabis and its extensive list of cannabinoids that have shown to have therapeutic effects in many areas.

The cannabinoid-based pharmaceutical research field is expected to reach $50 billion by 2029 , making cannabis research a very attractive venture for biotech companies of all sizes. Below, I am going to cover three of my favorite companies that are dabbling in the cannabinoid space in one way or another.

Cara Therapeutics ( CARA )

CARA is currently undergoing preclinical research in cannabinoids for the treatment of neuropathic pain as the treatment aligns with its overall values and mission to manage acute and chronic pain . While likely a successful candidate outside of the cannabis concept (currently with two Phase III trials underway, and two more in Phase II and one in Phase I ), its cannabinoid receptor agonist, CR701, focusing on CB1 and CB2 receptors could prove fruitful for the company.

CB1 receptors are mainly localized in the brain whereas CB2 receptors are found mainly in peripheral tissues which have been shown to be involved in pain and inflammatory responses. CARA is developing CR701 to selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors.

CR701 has been evaluated in a rodent model of neuropathic pain that is comparable to human conditions while showing that administration of CR701 to animals with neuropathy resulted in significant reversal of both hyperalgesia and allodynia.

The main objective of the drug is to become a replacement for opioids, which caused more than 33,000 deaths due to overdose in 2015. Announcing its initial move into the cannabis space in 2017, the company will not likely begin clinical trials in humans for another year or so. I think late 2020 we should see initiation of Phase I.

In Q1 2019, the company reported a net loss of $22 million , with total revenues of $4.4 million due to license and milestone fees related to agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. With roughly $156 million in cash and cash equivalents on hand at the end of Q1, the company projects that it can continue operations through Q4 2020. However, I see an offering likely in early 2020, especially if there is positive news surrounding Phase III results and submission of an NDA. This will launch its marketing efforts and continue to support research, putting the company in a good position despite diluting shares.

GW Pharmaceuticals (GWPH)

Considered the leader in cannabinoid research and development, GW Pharma produced the first ever FDA-approved cannabinoid drug Epidiolex , an oral solution that is approved to treat seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome in patients 2 years or older.

With a patient population of roughly 70,000, LGS and Dravet syndrome are difficult to treat and offer very little viable treatment options.

Epidiolex has coverage in over 80% of all commercial lives, roughly 145 million with 60%, with 4 of the 5 largest US payors having initiated coverage of Epidiolex with a PA to indication. Since FDA approval, all 50 U.S. States have rescheduled the drug and Epidiolex now has a projected gross price in the first year of $32,500.

Upcoming, GW Pharma is awaiting EMA regulatory approval with the brand name Epidiolex with launches in France, Germany, Italy, Spain and the UK this year. The past year has seen rolling regulation changes throughout Europe on its stance on cannabis, which entices investors to believe that European approval is imminent.

With a drug approved for two indications and two more in Phase II/III as well as three other drug candidates with a total of 8 indications together all in mid-stages of clinical trials, GW Pharma seems to have a very bright future and continue to be the leader of the cannabis research field. The early data all looks very promising. I believe a deep dive into the company and its pipeline is in order shortly.

The company finished 2018 with $591.5 million in cash and expects to push $400 million for operating expenses through 2019. The company will likely need an offering soon to raise capital in order to continue its pipeline research; however, 2019 will be filled with catalysts to mask any dilution. This should be a shining year for GW Pharmaceuticals. The company projects 11 catalysts throughout 2019, I think GW Pharmaceuticals has my pick for top contender in the research space.

AbbVie ( ABBV )

Perhaps the biggest hidden gem of the cannabinoid and cannabis research space, major pharmaceutical company AbbVie is indeed involved in the cannabis space. With its FDA-approved synthetic cannabis-based drug Marinol, which was developed to alleviate nausea and vomiting in chemotherapy patients while also helping AIDS patients maintain hunger, AbbVie has taken its place among the few companies with an actual product that is FDA-approved that is linked to cannabis.

Marinol is a proven drug, with a global market of $160 million in 2016 and is expected to grow dramatically based on increased drug availability, a change in public opinion toward medical cannabis, new methods of drug delivery and the results from new clinical trials, as reported by Zacks Small-Cap Research . However, there are competing companies that are attempting to take market share from AbbVie's longstanding drug which has been around for more than 25 years.

Outside of Marinol, the company also holds many patents involving cannabinoid compounds. A few of these patents include:

Treatment of cannabinoid receptor-related diseases
A therapy for reducing side effects when using cannabinoid receptor ligands

Quite possibly the safest bet in the cannabis sector, AbbVie is an already established pharmaceutical company with a robust pipeline that boasted an EPS of $2.14 for Q1 2019 and even offers a dividend that exceeds 5% yield. If you want to invest in the cannabis space but want to limit exposure to the "devil's lettuce," AbbVie might be the optimal choice.

Coming off a high of nearly $120 just over a year ago, the high yield and robust pipeline that AbbVie offers is very appealing.

Cara Therapeutics has the highest room for growth. With a large pipeline outside cannabinoid-related drug candidates and preclinical research ongoing, the company will likely see a major boost from positive data from CR701.
GW Pharmaceuticals has exploded off the approval of its flagship product Epidiolex and with a year filled with catalysts, 2019 will prove fruitful. I would watch this company closely as we enter Q2, likely to see big moves up.
AbbVie is the unknown cannabis company that is staying under the radar. With a high yield, fair market value price, and promising pipeline with growing revenues, this company is the safest investment option for those who want to gain exposure to the cannabis industry. Although keep in mind, that exposure is very minimal.

This article was written by

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Related stocks, related analysis, trending analysis, trending news.

See us on facebook
See us on twitter
See us on youtube
See us on linkedin
See us on instagram

Pilot study shows ketogenic diet improves severe mental illness

A small clinical trial led by Stanford Medicine found that the metabolic effects of a ketogenic diet may help stabilize the brain.

April 1, 2024 - By Nina Bai

A study led by researchers at Stanford Medicine showed that diet can help those with serious mental illness. nishihata

For people living with serious mental illness like schizophrenia or bipolar disorder, standard treatment with antipsychotic medications can be a double-edged sword. While these drugs help regulate brain chemistry, they often cause metabolic side effects such as insulin resistance and obesity, which are distressing enough that many patients stop taking the medications.

Now, a pilot study led by Stanford Medicine researchers has found that a ketogenic diet not only restores metabolic health in these patients as they continue their medications, but it further improves their psychiatric conditions. The results, published March 27 in Psychiatry Research , suggest that a dietary intervention can be a powerful aid in treating mental illness.

“It’s very promising and very encouraging that you can take back control of your illness in some way, aside from the usual standard of care,” said Shebani Sethi , MD, associate professor of psychiatry and behavioral sciences and the first author of the new paper.

The senior author of the paper is Laura Saslow, PhD, associate professor of health behavior and biological sciences at the University of Michigan.

Making the connection

Sethi, who is board certified in obesity and psychiatry, remembers when she first noticed the connection. As a medical student working in an obesity clinic, she saw a patient with treatment-resistant schizophrenia whose auditory hallucinations quieted on a ketogenic diet.

That prompted her to dig into the medical literature. There were only a few, decades-old case reports on using the ketogenic diet to treat schizophrenia, but there was a long track record of success in using ketogenic diets to treat epileptic seizures.

“The ketogenic diet has been proven to be effective for treatment-resistant epileptic seizures by reducing the excitability of neurons in the brain,” Sethi said. “We thought it would be worth exploring this treatment in psychiatric conditions.”

A few years later, Sethi coined the term metabolic psychiatry, a new field that approaches mental health from an energy conversion perspective.

Shebani Sethi

In the four-month pilot trial, Sethi’s team followed 21 adult participants who were diagnosed with schizophrenia or bipolar disorder, taking antipsychotic medications, and had a metabolic abnormality — such as weight gain, insulin resistance, hypertriglyceridemia, dyslipidemia or impaired glucose tolerance. The participants were instructed to follow a ketogenic diet, with approximately 10% of the calories from carbohydrates, 30% from protein and 60% from fat. They were not told to count calories.

“The focus of eating is on whole non-processed foods including protein and non-starchy vegetables, and not restricting fats,” said Sethi, who shared keto-friendly meal ideas with the participants. They were also given keto cookbooks and access to a health coach.

The research team tracked how well the participants followed the diet through weekly measures of blood ketone levels. (Ketones are acids produced when the body breaks down fat — instead of glucose — for energy.) By the end of the trial, 14 patients had been fully adherent, six were semi-adherent and only one was non-adherent.

The participants underwent a variety of psychiatric and metabolic assessments throughout the trial.

Before the trial, 29% of the participants met the criteria for metabolic syndrome, defined as having at least three of five conditions: abdominal obesity, elevated triglycerides, low HDL cholesterol, elevated blood pressure and elevated fasting glucose levels. After four months on a ketogenic diet, none of the participants had metabolic syndrome.

On average, the participants lost 10% of their body weight; reduced their waist circumference by 11% percent; and had lower blood pressure, body mass index, triglycerides, blood sugar levels and insulin resistance.

“We’re seeing huge changes,” Sethi said. “Even if you’re on antipsychotic drugs, we can still reverse the obesity, the metabolic syndrome, the insulin resistance. I think that’s very encouraging for patients.”

The participants reported improvements in their energy, sleep, mood and quality of life.

The psychiatric benefits were also striking. On average, the participants improved 31% on a psychiatrist rating of mental illness known as the clinical global impressions scale, with three-quarters of the group showing clinically meaningful improvement. Overall, the participants also reported better sleep and greater life satisfaction.

“The participants reported improvements in their energy, sleep, mood and quality of life,” Sethi said. “They feel healthier and more hopeful.”

The researchers were impressed that most of the participants stuck with the diet. “We saw more benefit with the adherent group compared with the semi-adherent group, indicating a potential dose-response relationship,” Sethi said.

Alternative fuel for the brain

There is increasing evidence that psychiatric diseases such as schizophrenia and bipolar disorder stem from metabolic deficits in the brain, which affect the excitability of neurons, Sethi said.

The researchers hypothesize that just as a ketogenic diet improves the rest of the body’s metabolism, it also improves the brain’s metabolism.

“Anything that improves metabolic health in general is probably going to improve brain health anyway,” Sethi said. “But the ketogenic diet can provide ketones as an alternative fuel to glucose for a brain with energy dysfunction.”

Likely there are multiple mechanisms at work, she added, and the main purpose of the small pilot trial is to help researchers detect signals that will guide the design of larger, more robust studies.

As a physician, Sethi cares for many patients with both serious mental illness and obesity or metabolic syndrome, but few studies have focused on this undertreated population.

She is the founder and director of the metabolic psychiatry clinic at Stanford Medicine.

“Many of my patients suffer from both illnesses, so my desire was to see if metabolic interventions could help them,” she said. “They are seeking more help. They are looking to just feel better.”

Researchers from the University of Michigan; the University of California, San Francisco; and Duke University contributed to the study.

The study was supported by Baszucki Group Research Fund, Keun Lau Fund and the Obesity Treatment Foundation.

About Stanford Medicine

Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu .

Artificial intelligence

Exploring ways AI is applied to health care

Supported by

Use of Abortion Pills Has Risen Significantly Post Roe, Research Shows

By Pam Belluck

Pam Belluck has been reporting about reproductive health for over a decade.

Share full article

On the eve of oral arguments in a Supreme Court case that could affect future access to abortion pills, new research shows the fast-growing use of medication abortion nationally and the many ways women have obtained access to the method since Roe v. Wade was overturned in June 2022.

The Details

A person pours pills out of a bottle into a gloved hand.

A study, published on Monday in the medical journal JAMA , found that the number of abortions using pills obtained outside the formal health system soared in the six months after the national right to abortion was overturned. Another report, published last week by the Guttmacher Institute , a research organization that supports abortion rights, found that medication abortions now account for nearly two-thirds of all abortions provided by the country’s formal health system, which includes clinics and telemedicine abortion services.

The JAMA study evaluated data from overseas telemedicine organizations, online vendors and networks of community volunteers that generally obtain pills from outside the United States. Before Roe was overturned, these avenues provided abortion pills to about 1,400 women per month, but in the six months afterward, the average jumped to 5,900 per month, the study reported.

Overall, the study found that while abortions in the formal health care system declined by about 32,000 from July through December 2022, much of that decline was offset by about 26,000 medication abortions from pills provided by sources outside the formal health system.

“We see what we see elsewhere in the world in the U.S. — that when anti-abortion laws go into effect, oftentimes outside of the formal health care setting is where people look, and the locus of care gets shifted,” said Dr. Abigail Aiken, who is an associate professor at the University of Texas at Austin and the lead author of the JAMA study.

The co-authors were a statistics professor at the university; the founder of Aid Access, a Europe-based organization that helped pioneer telemedicine abortion in the United States; and a leader of Plan C, an organization that provides consumers with information about medication abortion. Before publication, the study went through the rigorous peer review process required by a major medical journal.

The telemedicine organizations in the study evaluated prospective patients using written medical questionnaires, issued prescriptions from doctors who were typically in Europe and had pills shipped from pharmacies in India, generally charging about $100. Community networks typically asked for some information about the pregnancy and either delivered or mailed pills with detailed instructions, often for free.

Online vendors, which supplied a small percentage of the pills in the study and charged between $39 and $470, generally did not ask for women’s medical history and shipped the pills with the least detailed instructions. Vendors in the study were vetted by Plan C and found to be providing genuine abortion pills, Dr. Aiken said.

The Guttmacher report, focusing on the formal health care system, included data from clinics and telemedicine abortion services within the United States that provided abortion to patients who lived in or traveled to states with legal abortion between January and December 2023.

It found that pills accounted for 63 percent of those abortions, up from 53 percent in 2020. The total number of abortions in the report was over a million for the first time in more than a decade.

Why This Matters

Overall, the new reports suggest how rapidly the provision of abortion has adjusted amid post-Roe abortion bans in 14 states and tight restrictions in others.

The numbers may be an undercount and do not reflect the most recent shift: shield laws in six states allowing abortion providers to prescribe and mail pills to tens of thousands of women in states with bans without requiring them to travel. Since last summer, for example, Aid Access has stopped shipping medication from overseas and operating outside the formal health system; it is instead mailing pills to states with bans from within the United States with the protection of shield laws.

What’s Next

In the case that will be argued before the Supreme Court on Tuesday, the plaintiffs, who oppose abortion, are suing the Food and Drug Administration, seeking to block or drastically limit the availability of mifepristone, the first pill in the two-drug medication abortion regimen.

The JAMA study suggests that such a ruling could prompt more women to use avenues outside the formal American health care system, such as pills from other countries.

“There’s so many unknowns about what will happen with the decision,” Dr. Aiken said.

She added: “It’s possible that a decision by the Supreme Court in favor of the plaintiffs could have a knock-on effect where more people are looking to access outside the formal health care setting, either because they’re worried that access is going away or they’re having more trouble accessing the medications.”

Pam Belluck is a health and science reporter, covering a range of subjects, including reproductive health, long Covid, brain science, neurological disorders, mental health and genetics. More about Pam Belluck

Publication types

Case Reports

Public Health Roles to Pursue Before Medical School

Gap years before med school can be spent many ways, such as volunteering at nonprofit organizations or startup companies.

Public Health Roles Before Med School

Getty Images

There are opportunities in health research that potential medical school applicants can do before they apply.

Premedical students taking a gap year or years before medical school can consider pursuing public health opportunities to complement their patient care experiences.

Public health experiences equip future doctors with essential skills to address broader societal health care issues, such as health care disparities, infectious disease outbreaks, health effects of climate change, water sanitation and access to health care. Premeds can also gain insights into epidemiology , health policy and health promotion strategies.

Gap years are opportune times to pursue public health experiences because premeds can gain hands-on experiences rather than the more theoretical approach to public health offered during college courses.

During my first gap year after graduating from college, I wanted to apply the public health knowledge I had learned in the classroom and affect health care at the population level. Entering my gap years, I had some specific goals related to public health.

First, I wanted to learn how to build public health programs and initiatives. Second, I wanted to understand the dynamics among local health care clinics, governments and nongovernmental organizations. Third, I wanted to see how physicians could take their clinical insights and create public health programs to affect population-level changes. Finally, I was excited to learn as much about public health as possible.

So how did I pursue these objectives during my gap year and what public health initiatives did I pursue?

I spent my first gap year as a Fulbright scholar in the Philippines. I first sought out doctors who were involved in public health initiatives. I learned how their clinical experiences inspired their public health initiatives.

Second, I volunteered my time to help with any public health initiatives. From these volunteering opportunities, I gained on-the-ground experience with different public health projects. I learned how to create new public health initiatives and partnerships with other community organizations.

For example, I helped one doctor launch a national HIV awareness campaign in the Philippines facilitated by unique partnerships with the music industry and media. With another doctor, I traveled to rural Philippines to volunteer at a cervical cancer screening program she created for low-income women.

As I was helping physicians with their public health projects, I was pitching other health care leaders about a public health program I wanted to create – I had a vision to increase access to vaccinations, which was also the topic of my senior thesis research at Princeton University in New Jersey.

Through persistently telling everyone about my interest in vaccinations, I was able to work on a project with the World Health Organization on improving hepatitis B vaccine rates among newborns in Manila. I learned how to collaborate with organizations like the World Health Organization and city governments.

Finally, I was hungry to leverage every opportunity possible to learn more about a broad array of public health and global health topics. Any time I received an invite to a public health conference, I said yes. Every time a policy leader or doctor invited me to a public health meeting, I said yes. Every time I was offered a chance to volunteer at a public health event, I said yes.

During my gap year, I was essentially a public health sponge. I had a great year learning about topics ranging from nutrition to neonatal health to disaster medicine . I was able to pick the brains of health care leaders about public health and gain tips to make public health initiatives successful.

Premedical students often ask me about how I find public health opportunities. My first piece of advice is that premeds should network with other physicians involved with public health. While some opportunities are widely publicized, many are discovered through networking.

Here are common public health opportunities premed students can pursue during their gap years.

Public Health Research

Many medical schools and public health schools around the U.S. have faculty members who are engaged in public health research . Popular types include epidemiology, analyzing large data sets to understand health outcomes among different subsets of the population and analyzing the success of public health programs and initiatives.

Public Health Departments

Premed students can work for public health departments at the community, state or national level. National-level opportunities are found at organizations like the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

Gap year jobs at public health departments often include working on existing public health projects. For example, you can lead car seat safety classes in the community or prenatal classes for women.

Nonprofit and Nongovernmental Organizations

Premeds can work for large NGOs and nonprofits like the Bill & Melinda Gates Foundation, the Clinton Foundation or AmeriCorps, an independent agency of the U.S. government. Premeds can conduct research or health programming at these organizations.

There are also excellent public health opportunities at smaller, community-based nonprofits. They may have more niche opportunities and work with more specific populations, such as homeless people and individuals with disabilities or drug use disorders. As a premed working at a small nonprofit, your work will tackle initiatives toward improving the health of specific populations.

Startups and Other Companies

Many premed students don’t know that they can gain public health experience at private companies, particularly startups . For example, my mentees have worked at health education companies. Other mentees have worked for companies where they created and analyzed community-based public health programs.

Smaller companies are less likely to have official job postings. If premeds are interested in a specific company, I encourage them to reach out to the founder directly to see if there are opportunities. Chances are high that the companies are looking for bright, motivated talent!

Pursuing public health opportunities during gap years can be enriching. Learning about public health can help you translate your insights from patients you see in clinic to projects and research that can benefit entire populations.

Med Schools With the Highest MCAT Scores

A small group of medical student residents gather around a boardroom table to to meet with their medical team lead. They each have cases out on front of them as they work together collaboratively to discuss each one. They are each dressed professionally in medical scrubs and are listening attentively to the doctor leading the meeting at the head of the table.

About Medical School Admissions Doctor

Need a guide through the murky medical school admissions process? Medical School Admissions Doctor offers a roundup of expert and student voices in the field to guide prospective students in their pursuit of a medical education. The blog is currently authored by Dr. Ali Loftizadeh, Dr. Azadeh Salek and Zach Grimmett at Admissions Helpers , a provider of medical school application services; Dr. Renee Marinelli at MedSchoolCoach , a premed and med school admissions consultancy; Dr. Rachel Rizal, co-founder and CEO of the Cracking Med School Admissions consultancy; Dr. Cassie Kosarec at Varsity Tutors , an advertiser with U.S. News & World Report; Dr. Kathleen Franco, a med school emeritus professor and psychiatrist; and Liana Meffert, a fourth-year medical student at the University of Iowa's Carver College of Medicine and a writer for Admissions Helpers. Got a question? Email [email protected] .

Choosing A Major for Med School

Andrew Bauld March 26, 2024

Handling a Law School Rejection Letter

Gabriel Kuris March 25, 2024

College Majors and MBA Admissions

Anthony Todd Carlisle March 20, 2024

Tips While Awaiting Med School Decision

Zach Grimmett March 19, 2024

2024 Best Grad Schools Rankings Coming

Robert Morse and Eric Brooks March 19, 2024

Tips for Aspiring Lawyers in High School

Gabriel Kuris March 18, 2024

4 Surprising MBA Application Mistakes

Andrew Warner March 18, 2024

Types of Doctors Premeds Can Become

Jarek Rutz March 14, 2024

Applying to Law School as a Minority

Sammy Allen March 14, 2024

Partner with us
Apply Online

Pirogov Medical University

The university.

Recognitions
Eligibility
Fees Structure

Founded in 1906 in the city of Moscow, Pirogov Medical University—officially known as Russian National Research Medical University named after N. I. Pirogov— is one of the oldest medical universities in Russia. The first lecture took place on September 26, 1906, with 206 students, and the first graduation ceremony was celebrated in 1912. The University claims to be the first university in Russia that started offering medical education to women in the Russian Federation.It independently carries out various research projects in medicine and has received the status of National Research University in 2010.The Library of Pirogov Medical University has a collection of more than 7,50,000 books. For world-class clinical training and diverse practical exposure, the University collaborates with more 120 hospitals across the city of Moscow. Pirogov Medical University started accepting international students in 1959. Presently, more than 8,000 students are studying medicine at the University, out of which about 700 are international students. The University has a strong team of about 2,000 faculty members. Pirogov Medical University is approved by the Medical Council of India (MCI) and offers a 6-Year Program for MBBS in Russia. Students in India, who have qualified NEET, can apply for direct admission to the MBBS Program of Pirogov Medical University.

Ministry of Science and Higher Education, Russia

World Directory of Medical Schools (WDOMS)

Medical Council of India (MCI)

Foundation for Advancement of International Medical Education and Research (FAIMER)

To get admission to the MBBS Program of Pirogov Medical University, the student must qualify NEET-UG (National Eligibility cum Entrance Test-Undergraduate).

Besides NEET-UG, there is no requirement to go through any additional entrance examination.

RUS EDUCATION SUPPORT

INDIAN FOOD

MODERN CLASSROOMS

Medical Laboratories

Clinical Training

Recreational Facilities

Ensured Safety

FMGE (Foreign Medical Graduates Examination) Preparation

USMLE (United States Medical Licensing Examination) Preparation

Pirogov Medical University was founded in 1906 in the Moscow city of Russia.
In 1930, Pirogov Medical University organized the World’s first pediatric faculty.
In 1963, Pirogov Medical University organized the World’s first biomedical faculty.
In 2010, Pirogov Medical University received the status of National Research University.
Presently, more than 8,000 students are studying at Pirogov Medical University, out of which about 700 are international students.

University Address

Mbbs program, admission & support, medical licensing examination support, student life.

Focused on constantly improving the quality of education, the University entered the list of Times Higher Education World University Rankings and QS World University Rankings in 2019.

The University claims to be the first university in Russia that started offering medical education to women in the Russian Federation. Among all milestones achieved by the University, two most celebrated achievements are that Pirogov Medical University created the world’s first pediatric faculty in 1930 and the world’s first biomedical faculty in 1963.

To provide students and visitors a glimpse into the decades of the glorious history of the University, Museum of the History of Pirogov Medical University was established in 1981, which continues to capture astonishing achievements of the University, its students, and members.

The University maintains a leading position in Russia by actively participating in activities of medical research and healthcare and delivering excellence in medical education and care.

The University independently carries out various research projects in medicine and has received the status of National Research University in 2010. Conducting pre-clinical as well as clinical studies for a better understanding of human diseases, new medicines, and medical devices have been the center of research at Pirogov Medical University.

To keep the students and healthcare professionals updated on the latest research and innovations in medicine, the University publishes its own scientific journal with articles on biomedical sciences and clinical medicine.

The Library of Pirogov Medical University has a collection of more than 7,50,000 books. Students can also access scientific journals and eBooks through the electronic library system. In collaboration with other universities, academic mobility and exchange programs are also arranged for students to help them get experience in other institutions and build new connections.

For the healthcare of locals, the University operates clinical centers in Moscow. Students are provided hands-on clinical training in these University-operated clinics and also involved in various clinical studies. For world-class training and diverse practical exposure, the University collaborates with more 120 hospitals across the city of Moscow.

Pirogov Medical University started accepting international students in 1959. Until now, the University has trained more than 80,000 doctors. Presently, more than 8,000 students are studying medicine at the University, out of which about 700 are international students. The University has a strong team of about 2,000 faculty members.

Pirogov Medical University is listed in the World Directory of Medical Schools (WDOMS) and certified by the Educational Commission for Foreign Medical Graduates (ECFMG), United States of America. Pirogov Medical University is also approved by the Medical Council of Canada (MCC) and the Medical Council of India (MCI). The University offers a 6-Year Program for MBBS in Russia for local as well as international medical aspirants. Students in India, who have qualified NEET, can apply for direct admission to the MBBS Program of Pirogov Medical University.

Pirogov Medical University Faculty of Medicine 1 Ostrovityanov Str Moscow, 117997 Russian Federation

Pirogov Medical University offers a 6-Year MBBS Program in the Russian language. For international students, classes for initial years may be organized in English medium.

The Program for MBBS in Russia is focused on building a strong academic base with a pragmatic approach to education and medical research. To provide hands-on clinical experience, the students studying MBBS in Russia are involved in clinical training from the second year of MBBS. While education in classrooms and laboratories helps the students develop academic skills and sound theoretical understanding, clinical training in University-affiliated hospitals help them apply their knowledge into practice.

To get admission to the MBBS Program of Pirogov Medical University, you can apply online at Rus Education website.

Rus Education is duly authorized by the Russian Centre for Science and Culture (Cultural Department of The Embassy of the Russian Federation in India) to promote Russian Education among Indian Citizens. Rus Education is also an authorized associate of Pirogov Medical University. We facilitate one-window admission to the MBBS Program of Pirogov Medical University with no requirement of any donation or capitation and without any entrance examination.

Pirogov Medical University offers a healthy student life and an opportunity to experience life in Moscow, the capital city of Russia, and also the most vibrant and exciting location in the largest country in the world!

For affordable accommodation of students and make their living experience safe and better, the University maintains a comfortable dormitory. Every room is shared by two or three students, and each floor has a shared kitchen where students can cook their food. Members of the dormitory help the newcomers to settle in their new homes. For the safety of the students, the University’s security team maintains 24-hour surveillance and is capable of providing emergency response, if required.

To help students adjust to life at university, it has a dedicated Student Support System in place. Every group of new students is assigned to two professors who guide the students not only about studying but about living as well, helping students adjust to the new environment and feel comfortable.

To keep students fit and active, Sports Center on the campus is equipped with facilities to play various sports, including badminton, basketball, volleyball, table tennis, swimming, football, hockey, chess, etc. Student can unleash their creativity by indulging in extracurricular adventures offered by Student Organizations and Societies. On the campus, there are ample opportunities for self-improvement and taking part in music, dance, sports competitions, and theater.

For peer support, the University has a Student Council in place which offers support in academic as well as non-academic matters making student life stress free.

For the social upliftment and help students connect with the society and local people, they are involved in community and welfare organized by the University, including medical outreach, health awareness programs, and blood donation camps. The University Volunteer Center organizes a number of volunteer activities to help students contribute to social causes.

Living in Moscow, students can explore its cultural heritage, museums, historic buildings, the world-famous Alexander Garden, and much more. For traveling in Moscow, students don’t face any problems, thanks to its convenient and cheap transportation system, especially the Moscow Metro.

With the charm of Moscow and all the student facilities and support services offered by the University, student life at Pirogov Medical University is a delight.

TOP MEDICAL UNIVERSITIES IN RUSSIA

Perm State Medical University

Tver State Medical University

Orenburg State Medical University

Mari State University

Siberian State Medical University

A php error was encountered.

Severity: Notice

Message: Undefined variable: countries

Filename: includes/footer.php

Line Number: 26

File: /home/mbbsinrussia/public_html/application/views/includes/footer.php Line: 26 Function: _error_handler

File: /home/mbbsinrussia/public_html/application/controllers/University.php Line: 46 Function: view

File: /home/mbbsinrussia/public_html/index.php Line: 315 Function: require_once

Severity: Warning

Message: Invalid argument supplied for foreach()

Message: Undefined variable: state

Line Number: 44

File: /home/mbbsinrussia/public_html/application/views/includes/footer.php Line: 44 Function: _error_handler

IMAGES

Test tubes in clinic, pharmacy and medical research laboratory
Top 8 Precision Medicine Companies in the USA I Industry Wired
Fresenius medical care logo 2021
The Leading Medical Companies to Watch Out for in 2019
Infographic: The 6 Forces Transforming the Future of Healthcare
Pharmaceutical Clinical Reseach Lists

VIDEO

Top 10 Medical Device Companies in 2023 by Revenue Statistics and Trends
Family Medicine Opportunity in Virginia

COMMENTS

Top 15 Clinical Research Companies: Leaders in Medical Innovation
1. IQVIA. IQVIA is a global leader in clinical research and healthcare data analytics. They play a crucial role in the medical field by providing comprehensive data, advanced analytics, and expert insights. This helps pharmaceutical and healthcare companies make smarter, more effective decisions.
28 Top Biotech Companies Bolstering Life Sciences
Takeda. Lexington, Massachusetts. Founded in the 18th century, Takeda is a global pharmaceutical company with a strong emphasis on research and development. The company focuses its research in several areas: oncology, rare diseases, plasma-derived therapies, vaccines, neuroscience and gastroenterology.
The 10 most innovative biotech companies of 2021
The 10 most innovative biotech companies of 2021. Why Pfizer, Moderna, and Oxford-AstraZeneca top our 2021 list.
Top 17 Clinical Research Organizations in 2022 [Ultimate Guide]
1. IQVIA. Formerly known as Quintiles and IMS Health, IQVIA is one of the largest CROs in the world, with a large range of service offerings to help advance clinical research. The company was founded in North Carolina in 1982, and has since grown to over 88,000 employees in more than 100 countries.
Top companies sponsoring clinical trials and medical advancement
Biotechnology companies such as Amgen, Gilead Sciences, and Moderna also play a vital role in sponsoring clinical trials. With a focus on innovative therapies and cutting-edge research, biotech companies contribute to advancing medical science. They often specialize in developing novel drugs and therapies, particularly in areas with unmet ...
131 Clinical Research Companies Worldwide
View the list and locations of 131 biotechnology companies engaged in Clinical Research work. View the directory and locations for 132 biotechnology companies engaged in Clinical Research work. ... Medical Devices (1) Molecular Diagnostics (1) Oncology (1) Pharmaceuticals (1) Pharmacogenomics (1) Regenerative Medicine (1) Regulatory Consulting ...
The 10 most innovative medicine and therapeutics companies of 2022
At the same time, companies are beginning to redefine what it means to be medicine. Software is starting to treat physical ailments just like pills do. And yes, companies continued to find ways to ...
11 clinical trials that will shape medicine in 2023
Nature Medicine asks leading researchers to name their top clinical trial for 2023, from cervical and prostate cancer screening to new drugs for Parkinson's disease and Alzheimer's disease.
11 clinical trials that will shape medicine in 2024
Patients referred from primary care for chest X-ray are included for analysis by the AI. We will complete recruitment in July 2024, and we hope to have results in 2024. Our hypothesis, based on ...
22 Top Health Care Research Companies 2021
The Medical Research Group at Decision Analyst specializes in qualitative investigations, strategic survey research, advanced analytics and consulting services for the pharmaceutical, medical, health and wellness industries. ... We are one of the Top 25 Most Innovative Research Companies and a Top 10 Strategic Consultancy, according to ...
Medical Research
Medical Research Issues. The AAMC is a leading voice and advocate for the full spectrum of medical research. We work with federal policy makers to ensure that our members' perspective is incorporated into federal legislation and regulation. Regulating Research. Basic Science. Research Training. Stem Cell Research. Research Evaluation.
NIH partners with 11 leading biopharmaceutical companies to accelerate
The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. ... the nation's medical research agency, includes 27 Institutes and Centers and is a ...
15 Biggest Neuroscience Companies in the World
NBIX. Neurocrine Biosciences, Inc. 140.25. -1.18. -0.83%. In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to ...
10 List of Clinical Research Organizations in the US
List of clinical research organizations in the US. 1. IQVIA. IQVIA is a globally renowned medical research companies in USA that stands out for its exceptional contributions to the healthcare and pharmaceutical industries. As one of the leading providers of advanced analytics, technology solutions, and contract research services, IQVIA plays a ...
List of largest biomedical companies by revenue
The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$10 billion, ranked by their revenue in the respective financial year.. It does not include biotechnology companies that are now owned by, or form a part of, larger pharmaceutical groups.
Clinical Trial Services
A contract research organization (CRO) is crucial to medical research and development to provide support that includes clinical trial management and CRO research. ... and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a ...
The Top 10 Clinical Research Companies in USA
Founded: 1982 Headquarters: Waltham, Massachusetts Annual Revenue: $3B Employee Size: 18,000 Parexel is another important name in the list of Clinical Research Companies In USA that specializes on behalf of its pharmaceutical partners in carrying out clinical studies to boost and make certain that the medicine approval process takes place smoothly. It has a wide range of offerings that spreads ...
5 Companies Pioneering Breakthrough Cancer Research
5 Companies Pioneering Cancer Research 1.) Genentech (Roche): Genentech, a leading biotechnology company, is spearheading cancer research with its groundbreaking advancements in personalized medicine and targeted therapies. Through extensive genomic analysis and precision medicine approaches, Genentech focuses on developing therapies tailored ...
How patient-led research could speed up medical innovation
A history of patient activism and patient-led research. About 1.3 percent of adults in the United States have ME/CFS, according to the U.S. Centers for Disease Control and Prevention.
My Top 3 Companies Paving The Way For Medicinal Cannabis Research
In Q1 2019, the company reported a net loss of $22 million, with total revenues of $4.4 million due to license and milestone fees related to agreement with Vifor Fresenius Medical Care Renal ...
Stop COVID Cohort: An Observational Study of 3480 Patients ...
Affiliations 1 Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.; 2 Inflammation, Repair, and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom.
Pilot study shows ketogenic diet improves severe mental illness
About Stanford Medicine. Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients.
Use of Abortion Pills Has Risen Significantly Post Roe, Research Shows
The News. On the eve of oral arguments in a Supreme Court case that could affect future access to abortion pills, new research shows the fast-growing use of medication abortion nationally and the ...
Pirogov Russian National Research Medical University, Moscow City
Students can undergo a mandatory annual medical examination at the polyclinic. Diagnostic Medical Center №1, located at ul. Miklouho-Maclay 29 bldg. 2, provides round-the-clock emergency medical care for students living in University dormitory. Emergency phone number: + 7-495-330-80-65 (around the clock).
Interstitial inflammation and pulmonary fibrosis in COVID-19: The
4 Chief Medical Officer of City Clinical Hospital No. 52 of Moscow Healthcare Department, 3 Pekhotnaya Street, Moscow, 123182, Russia. 5 Department of Internal Medicine, Faculty of Additional Professional Education at Federal State Autonomous Educational Institution of Higher Education Pirogov Russian National Research Medical University, 1 ...
Public Health Roles to Pursue Before Medical School
Many medical schools and public health schools around the U.S. have faculty members who are engaged in public health research. Popular types include epidemiology, analyzing large data sets to ...
Pirogov Medical University
Founded in 1906 in the city of Moscow, Pirogov Medical University—officially known as Russian National Research Medical University named after N. I. Pirogov— is one of the oldest medical universities in Russia. The first lecture took place on September 26, 1906, with 206 students, and the first graduation ceremony was celebrated in 1912.
Why Medical Properties Trust Popped This Week
Shares of hospital real estate investment trust (REIT) Medical Properties Trust (MPW-0.42%) rallied this week, appreciating 15.1% through 12:46 p.m. ET Thursday, according to data from S&P Global ...
Food as medicine: Medically tailored meals may get standardized
(Slavin, who served on the 2010 committee that determines the national dietary guidelines, has received research funding from companies that produce ultra-processed products and those with ...
NVIDIA Announces Project GR00T Foundation Model for Humanoid Robots and
The company's invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined computer graphics, ignited the era of modern AI and is fueling industrial digitalization across markets. NVIDIA is now a full-stack computing infrastructure company with data-center-scale offerings that are reshaping industry.

Top 15 Clinical Research Companies: Leaders in Medical Innovation

Quick List of Top 15 Clinical Research Companies

3 Best Clinical Research Organizations: Comparison Chart

3 Top Clinical Research Organization List For Advanced Medical Discoveries

About IQVIA

Features of IQVIA

Innovative Clinical Development

Efficient Payment Systems for Clinical Trials

Decentralized Trials Expertise

Global Reach and Impact

AI and Technology Integration

Our Review of IQVIA

Features of ICON

Diverse Clinical and Scientific Operations

Decentralized Clinical Trial Solutions

Specialized Therapeutic Areas

Innovative Solutions for Biotech

Advanced Medical Imaging Solutions

Our Review of ICON

About Parexel

Features of Parexel

Patient-Centric Approach

Innovative Trial Designs

Regulatory Compliance and Market Access

Patient Advocacy and Engagement

Focus on Speed and Precision

Our Review of Parexel

Other 12 Companies of Clinical Research

1. Syneos Health

About Syneos Health

About Labcorp

About Medpace

5. Charles River Laboratories

About Charles River Laboratories

6. PRA Health Science

About PRA Health Science

7. AdvanCell

About AdvanCell

About Dynata

About Covance

About MedNet

11. Fisher Clinical Services Inc.

About Fisher Clinical Services Inc.

12. Worldwide Clinical Trials

About Worldwide Clinical Trials

What To Consider When Choosing the Best Clinical Research Companies?

Expertise and Specialization

Regulatory Compliance

Reputation and Track Record

Project Management Capabilities

Patient Recruitment Strategies

Data Management and Analysis

Cost and Financial Terms

How Heartbeat AI Can Help You Get the Best List of Clinical Research Organizations?

Data Analysis and Processing

Machine Learning Algorithms

Predictive Analytics

Customization and Personalization

Real-time Data Updates

Integration with External Databases

Frequently Asked Question

What is the role of a clinical research coordinator?

What is informed consent in clinical research?

Leave a Reply Cancel reply

Enter your account information

Enter your phone number

28 Biotech Companies Bolstering Life Sciences

Biotech Companies to Know

Novo Nordisk

Schrödinger, Inc.

Viome Life Sciences

Variant Bio

Charles River Laboratories

Imagen Technologies

ATX Therapeutics

Strata Oncology

Myriad Genetics

Great Companies Need Great People. That's Where We Come In.

Top 17 Clinical Research Organizations (CRO) in 2023

3. PRA Health Sciences